

BF

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07H 21/00		A1	(11) International Publication Number: WO 96/40709 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/07844 (22) International Filing Date: 29 May 1996 (29.05.96)		(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/480,228 7 June 1995 (07.06.95) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: PERSEPTIVE BIOSYSTEMS, INC. [US/US]; 500 Old Connecticut Path, Framingham, MA 01701 (US).			
(72) Inventors: GILDEA, Brian, D.; 96 Pheasant Road, Billerica, MA 01821 (US). COULL, James, M.; 7 Banbury Drive, Westford, MA 01886 (US).			
(74) Agent: TURANO, Thomas, A.; Testa, Hurwitz & Thibeault, L.L.P., High Street Tower, 125 High Street, Boston, MA 02110 (US).			

(54) Title: PNA-DNA CHIMERAS AND PNA SYNTONS FOR THEIR PREPARATION

(57) Abstract

A method is disclosed for the preparation of novel PNA synthons compatible with DNA synthetic reagents and instrumentation. Accordingly, the PNA synthons of this invention are particularly suitable for the preparation of PNA-DNA chimeras, among other oligomers. The PNA synthons are designed to have a protecting group strategy which is orthogonal and allows removal of the protecting groups under mild conditions. Generally, an acid labile protected backbone is coupled to a nucleobase side chain moiety to form the PNA synthon. A novel method for synthesizing the acid labile protected backbone also is described. In addition, novel compositions of matter are disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

PNA-DNA CHIMERAS AND PNA SYNTHONS FOR THEIR PREPARATION

Background of the Invention

1. Field of the Invention

This invention relates to the field of Peptide Nucleic Acid (PNA) synthesis. More particularly, this invention relates to PNA synthons suitable for the synthesis and deprotection of PNA-DNA chimeras.

2. Description of the Background Art

Peptide Nucleic Acids (PNAs) are synthetic polyamides which are promising candidates for the sequence-specific regulation of DNA expression and for the preparation of gene targeted drugs. See European Patent applications EP 92/01219 and 92/01220 which are herein incorporated by reference. PNAs are biopolymer hybrids which possess a peptide-like backbone to which the nucleobases of DNA are attached. Specifically, PNAs are synthetic polyamides comprised of repeating units of the amino acid, N-(2-aminoethyl)-glycine, to which the nucleobases adenine, cytosine, guanine, thymine and uracil are attached through a methylene carbonyl group. Other natural and unnatural nucleobases, such as pseudo isocytosine, 5-methyl cytosine, pseudouracil, isocytosine, hypoxanthine and 2,6-diaminopurine, among many others, also can be incorporated in PNA synthons (see Figure 8).

PNAs are now routinely synthesized from monomers (PNA synthons) protected according to the t-Boc/benzyl protection strategy, wherein the backbone amino group of the growing polymer is protected with the t-butyloxycarbonyl (t-Boc) group and the exocyclic amino groups of the nucleobases, if present, are protected with the benzyloxycarbonyl (benzyl) group. PNA synthons protected using the t-Boc/benzyl strategy are now commercially available but are inconvenient to use because, among other reasons, harsh acidic conditions are required to remove these protecting groups.

The t-Boc/benzyl protection strategy requires very strong acids to remove all of the benzyl side chain nucleobase protecting groups. Typically, PNA oligomers are exposed to hydrofluoric acid or trifluoromethane sulfonic acid for periods of time often exceeding one hour to completely

- 2 -

remove the benzyl side chain protecting groups. This harsh acid treatment needed for final deprotection will often decompose, among other acid sensitive moieties, nucleic acids and carbohydrates which might be attached to the nucleic acid oligomer. Furthermore, the use of hazardous acids such as hydrofluoric acid or trifluoromethane sulfonic acid is not commercially

- 5 embraced in view of safety concerns for the operators and the corrosive effect on automation equipment and lines. The above described harsh conditions are particularly unsuitable for the synthesis of nucleic acids since the strong acid deprotection conditions will at least partially decompose nucleic acids.

In addition, the t-Boc/benzyl protection strategy is not orthogonal but differential. A

- 10 differential strategy is defined as a system of protecting groups wherein the protecting groups are removed by essentially the same type of reagent or condition, but rely on the different relative rates of reaction to remove one group over the other. For example, in the t-Boc/benzyl protecting strategy, both protecting groups are acid labile, with benzyl groups requiring a stronger acid for efficient removal. When acid is used to completely remove the more acid labile t-Boc
- 15 protecting groups, there is a potential that a percentage of benzyl groups will also be removed contemporaneously. Specifically, the t-Boc protecting group must be removed from the amino group backbone during each synthetic cycle so the next monomer can be attached to the backbone at the free amino site thereby allowing the polymeric chain to grow. The deprotection of the t-Boc amino protected backbone is accomplished using a strong acid such as trifluoroacetic acid.

- 20 During this deprotection and subsequent construction of the PNA oligomer, removal of the nucleobase side chain protecting groups, i.e., the benzylic, is undesirable. However, trifluoroacetic acid is potentially strong enough to prematurely deprotect a percentage of the side chain benzyl groups, thereby introducing the possibility of polymer branching and reducing the overall yield of desired product.

- 25 An orthogonal strategy, on the other hand, removes the protecting groups under mutually exclusive conditions, e.g., one group is removed with acid while the other group is removed with base. Breipohl et al. have described an orthogonally protected PNA synthon using 9-fluorenylmethyloxycarbonyl (Fmoc) as the backbone protecting group and a triphenylmethyl (trityl) group as the side chain nucleobase protecting group. Breipohl et al. 1st Australian Peptide Conference, Great Barrier Reef, Australia, October 16-21, 1994. This protection methodology, however, is incompatible with standard nucleic acid synthesis methodology.

- 3 -

- Christensen et al. have described orthogonal PNA synthons wherein the t-Boc amino backbone protecting group is removed in strong acid then reprotected with 9-fluorenylmethyloxycarbonyl (Fmoc), a base labile protecting group. Christensen, L. et al. "Innovation and Perspectives in Solid Phase Synthesis and Complementary Technologies-Biological and Biomedical Applications," 3rd SPS Oxford Symposia (1994). Although this protection strategy eliminates the potential for premature deprotection of the exocyclic amino group of the side chain nucleobase, extra steps are involved in preparation of this monomer. Additionally, strong acids such as hydrofluoric acid or trifluoromethane sulfonic acid still are required to remove the benzyl side chain protecting groups.
- 10 Nucleic acids (DNA and RNA) are now routinely synthesized using automated machines, numerous synthesis supports and various protection chemistries. The following U.S. patents cover a broad range of differing supports and protection chemistries and are herein incorporated by reference. U.S. Patent Nos. 5,262,530; 4,415,732; 4,458,066; 4,725,677 (RE 34,069); and 4,923,901. Automated equipment and reagents are commercially available from PerSeptive
- 15 Biosystems, Perkin Elmer (Applied Biosystems Division) and Pharmacia. Special 5'-amino synthons are described in Smith et al., Nucleic Acids Res. (1985) 13:2399 and in Sproat et al., Nucleic Acids Res. (1987) 15:6181. Special 5'-thio synthons are described in Sproat et al., Nucleic Acids Res. (1987) 15:4837. The reagents described in the above references are suitable for use on standard DNA synthesis instruments.
- 20 The preferred commercial method for nucleic acid synthesis utilizes the above reagents and methods as generally described by Koester et al. in U.S. Patent No. 4,725,677 (RE 34,069). Consequently, the preferred synthons are β -cyanoethyl phosphoramidites having acid labile protection of the backbone 5' hydroxyl group and base labile acyl-type protection of the exocyclic amino groups of the nucleobases.
- 25 The preferred acid labile backbone protecting group is 4,4'-dimethoxytriphenylmethyl (DMT). DMT is typically chosen because it can be removed fairly rapidly (1-3 minutes) during each synthetic cycle with solutions containing 1-4% dichloroacetic acid or trichloroacetic acid in dichloromethane. Protecting groups with increased acid lability compared to DMT are susceptible to premature deprotection during the acid catalyzed coupling reactions (tetrazole is
- 30 typically the acidic species). Protecting groups with decreased acid lability compared to DMT require longer reaction times and/or harsher reaction conditions for complete removal. Generally, harsher acidic deprotection conditions are avoided since the purine nucleobases are particularly

- 4 -

susceptible to decomposition in acid. Although the aforementioned problems with protecting groups and synthetic conditions may be minimal during each synthetic cycle, the cumulative effect can generate significant impurities in oligonucleotide synthesis. Accordingly, as the length of the oligonucleotide increases, its purity tends to decrease.

5 Generally, base labile protecting groups are utilized for protection of the exocyclic amino groups of the nucleobases so that an orthogonally protected nucleic acid synthon results. The base labile protecting groups typically remain a part of the growing nucleic acid chain, then are removed simultaneously with the cleavage of synthesized nucleic acid from the solid support. A concentrated ammonium hydroxide solution is often used for the "deprotection and cleavage
10 step." Koester et al. used base labile acyl-type protecting groups which are usually treated for 6-24 hours at elevated temperature (about 55°C) for complete removal of these nucleobase
protecting groups. Other protecting groups have been developed which are removed under the same conditions but in less time (from about 15-60 minutes). Examples of these improved
15 protecting groups include phenoxyacetyl, t-butyl phenoxyacetyl and amindine-type protecting
groups. While these protecting groups have increased base lability, typically only the time
necessary for removal is reduced.

Following from the above discussion, PNA synthons suitable for the construction of various nucleic acid oligomers should be compatible with current DNA synthetic methodologies so existing techniques and equipment can be utilized. Specifically, an appropriately acid labile
20 protecting group for backbone protection and an appropriate base labile protecting group for nucleobase protection need to be incorporated into the design of a PNA synthon. The ability to synthesize PNA synthons to meet the above requirements would allow various combinations of nucleic acids to be routinely synthesized and, consequently, allow the expansion of scientific investigations into the utility of these complex molecules.

25 Another current limitation on the synthesis of PNA synthons is the formation of the side chain nucleobase protecting group. Generally, the exocyclic amino groups of the nucleobases, e.g., cytosine, adenine, and guanine, are protected as carbamates via reaction with activated carbonates or chloroformates. This method of carbamate formation suffers from the disadvantage that many chloroformates are unstable or that the chloroformates are not appreciably reactive
30 with the mildly nucleophilic exocyclic amino groups of the nucleobases. Other methods of carbamate formation used for nucleobases include the use of imidazolides and alkyl imidazolium salts as acylating agents. See Watkins et al, J. Org. Chem., (1982) 47:4471-77 and Watkins et

- 5 -

al., J. Am. Chem. Soc., (1982) 104:5702-08. While imidazolides and alkylated imidazolides appear to overcome some of the difficulties associated with carbamate formation, their widespread use with nucleobases has yet to be reported. Recently, the 4-methoxy-triphenylmethyl (MMT) group was presented as another exocyclic amino protecting group for PNA synthon side chain nucleobases. Breipohl et al. 1st Australian Peptide Conference, Great Barrier Reef, Australia, October 16-21, 1994. The MMT group, however, is not a carbamate protecting group.

In addition to the above, the synthesis of a selectively protected guanine PNA synthon has been elusive. The reported guanine PNA synthons are protected as O-6-benzyl ethers but optionally possess benzyl protection of the exocyclic 2-amino group. See European Patent Application EP 92/01219 and United States Patent Applications PCT/US92/10921. Given the relative reactivity of the C6 carbonyl group (enol form) and the more reactive exocyclic 2-amino group, there is no compelling reason for protecting the C6 carbonyl group during PNA synthesis, whereas protection of the more reactive 2-amino group is preferred. There is presently no known method for synthesizing a guanine PNA synthon having selective benzyl protection (or other carbamate protection) of the exocyclic 2-amino group of the heterocycle.

The benzyloxycarbonyl group has been utilized in DNA synthesis for the protection of the exocyclic amino groups of the nucleobases cytosine, adenine and guanine. See Watkins et al, J. Org. Chem., (1982) 47:4471-77 and Watkins et al., J. Am. Chem. Soc., (1982) 104:5702-08. Nonetheless, the guanine synthon was difficult to prepare because the exocyclic 2-amino group of guanine was not reactive toward reagents routinely used to introduce the benzyl group, such as benzyl chloroformate, benzyloxycarbonyl imidazolide and N-alkylated benzyloxycarbonyl imidazole. Consequently, a non-conventional multi-step procedure was described wherein treatment with phenyl chlorothioformate simultaneously protected both the C6 carbonyl group and the exocyclic 2-amino group. Thereafter, the adduct was converted to a carbamate protected guanine compound whereby the C6 carbonyl protecting group was subsequently removed. Nonetheless, this indirect method is laborious because it requires the formation of a carbamate protecting group from the initial adduct and the subsequent deprotection of the C6 carbonyl group.

Suitably protected derivatives of 2-amino-6-chloropurine may be converted to guanine compounds by displacement of the 6-chloro group with oxygen nucleophiles. See Robins et al, J. Am. Chem. Soc. (1965) 87:4934, Reese et al., Nucl. Acids Res., (1981) 9: 4611 and Hodge et al., J. Org. Chem., (1990) 56:1553. Indeed, suitably protected derivatives of 2-amino-6-

- 6 -

chloropurine are the starting materials currently described for preparation of the reported guanine PNA synthons. See European Patent Application EP 92/ 01219 and United States Patent Application PCT/ US 92/10921.

The inventors of PNA describe a guanine synthon having no protection of the exocyclic 2-amino group but having the C6 carbonyl group protected as a benzyl ether. See European Patent Application EP 92/01219. This protection strategy is surprising because the more reactive 2-amino group will likely react (at least marginally) with the activated carboxylic acid group of other PNA monomers, thereby causing branching of the synthesized polymer. Conversely, the enol, which exists when the C6 carbonyl group remains unprotected, is not reactive enough to result in polymer branching and therefore should require no protection. Consequently, but for an inability to protect the exocyclic 2-amino group of guanine, the inventors chose an approach which is inconsistent with t-Boc/benzyl protection strategy they employed for the other PNA synthons.

In a more recent patent application, the guanine PNA synthon has both benzyl protection of the exocyclic 2-amino group and a C6 carbonyl group protected as a benzyl ether. See United States Patent Application PCT/US 92/10921. As previously discussed, there is no compelling rationale for protecting the C6 carbonyl group of the guanine PNA synthon. However, protection of the C6 carbonyl group enables selective ionization of the exocyclic 2-amino group of the guanine heterocycle thereby facilitating the reaction of the ionized 2-amino group with conventional benzyl protecting reagents (e.g. benzyloxycarbonyl imidazole). Nonetheless, protection of the exocyclic 2-amino group occurs on a guanine derivative additionally protected at the C6 carbonyl group of the nucleobase. Thus, the resulting synthon has both exocyclic 2-amino group and C6 carbonyl group protection. Hence, there remains no reported convenient high yield synthesis of a guanine PNA synthon having selective carbamate protection of the exocyclic 2-amino group, wherein the C6 carbonyl group remains unprotected.

Solid phase peptide synthesis methodology is applicable to the synthesis of PNA oligomers, but often requires the use of harsh reaction conditions unsuitable for DNA synthesis, and consequently, PNA-DNA chimera synthesis too. In the above-mentioned t-Boc/benzyl protection scheme, the final deprotection of side-chains and release of the PNA molecule from the solid support is most often carried out by the use of strong acids such as anhydrous hydrofluoric acid (HF) (Sakakibara, et al., *Bull. Chem. Soc. Jpn.*, 1965, 38, 4921), boron tris (trifluoroacetate) (Pless, et al., *Helv. Chim. Acta*, 1973, 46, 1609), and sulfonic acids such as

- 7 -

- trifluoromethanesulfonic acid and methanesulfonic acid (Yajima, et al., *J. Chem. Soc., Chem. Comm.*, 1974, 107). This conventional strong acid (e.g., anhydrous HF) deprotection method, produces very reactive carbocations that may lead to alkylation and acylation of sensitive residues in the PNA chain. Such side-reactions are only partly avoided by the presence of scavengers such as anisole, phenol, dimethyl sulfide, and mercaptoethanol. Thus, the sulfide-assisted acidolytic S_N2 deprotection method (Tam, et al., *J. Am. Chem. Soc.*, 1983, 105, 6442 and *J. Am. Chem. Soc.*, 1986, 108, 5242), the so-called "low," which removes the precursors of harmful carbocations to form inert sulfonium salts, is frequently employed in peptide and PNA synthesis, either solely or in combination with "high" methods. Less frequently, in special cases, other methods used for deprotection and/or final cleavage of the PNA-solid support bond are, for example, such methods as base-catalyzed alcoholysis (Barton, et al., *J. Am. Chem. Soc.*, 1973, 95, 4501), and ammonolysis as well as hydrazinolysis (Bodanszky, et al., *Chem., Ind.*, 1964, 1423), hydrogenolysis (Jones, *Tetrahedron Lett.*, 1977, 2853 and Schlatter, et al., *Tetrahedron Lett.*, 1977, 2861), and photolysis (Rich and Gurwara, *J. Am. Chem. Soc.*, 1975, 97, 1575)).
- 15 Based on the recognition that most operations are identical in the synthetic cycles of solid-phase peptide synthesis (as is also the case for solid-phase PNA), a new matrix, PEPS, was recently introduced (Berg, et al., *J. Am. Chem. Soc.*, 1989, 111, 8024 and International Patent Application WO 90/02749) to facilitate the preparation of large numbers of peptides. This matrix is comprised of a polyethylene (PE) film with pendant long-chain polystyrene (PS) grafts (molecular weight on the order of 10⁶). The loading capacity of the film is as high as that of a beaded matrix, but PEPS has the additional flexibility to suit multiple syntheses simultaneously.
- 20 Two other methods proposed for the simultaneous synthesis of large numbers of peptides also apply to the preparation of multiple, different PNA molecules. The first of these methods (Geysen, et al., *Proc. Natl. Acad. Sci. USA*, 1984, 81, 3998) utilizes acrylic acid-grafted polyethylene-rods and 96-microtiter wells to immobilize the growing peptide chains and to perform the compartmentalized synthesis. While highly effective, the method is only applicable on a microgram scale. The second method (Houghten, *Proc. Natl. Acad. Sci. USA*, 1984, 82, 5131) utilizes a "tea bag" containing traditionally-used polymer beads. Other relevant proposals for multiple peptide or PNA synthesis include the simultaneous use of two different supports with different densities (Tregear, in "*Chemistry and Biology of Peptides*," J. Meienhofer, ed., Ann Arbor Sci., Publ., Ann Arbor, 1972, pp. 175-178), combining of reaction vessels via a manifold (Gordman, *Anal. Biochem.*, 1984, 136, 397), multicolumn solid-phase synthesis (e.g. Krchnak, et

- 8 -

al., *Int. J. Peptide Protein Res.*, 1989, 33, 209), and Holm and Meldal, in "Proceedings of the 20th European Peptide Symposium," G. Jung and E. Bayer, eds., Walter de Gruyter & Co., Berlin, 1989, pp. 208-210), and the use of cellulose paper (Eichler, et al., *Collect. Czech. Chem. Commun.*, 1989, 54, 1746).

5 While the conventional cross-linked styrene/divinylbenzene copolymer matrix and the PEPS supports are presently preferred in the context of solid-phase PNA synthesis, a nonlimiting list of examples of solid supports which may be of relevance are: (1) Particles based upon copolymers of dimethylacrylamide cross-linked with N,N'-bisacryloylethylenediamine, including a known amount of N-tertbutoxycarbonyl-beta-alanyl N'-acryloylhexamethylenediamine. Several
10 spacer molecules are typically added via the beta alanyl group, followed thereafter by the amino acid residue moieties. Also, the beta alanyl-containing monomer can be replaced with an acryloyl sarcosine monomer during polymerization to form resin beads. The polymerization is followed by reaction of the beads with ethylenediamine to form resin particles that contain primary amines as the covalently linked functionality. The polyacrylamide-based supports are relatively more
15 hydrophilic than are the polystyrene-based supports and are usually used with polar aprotic solvents including dimethylformamide, dimethylacetamide, N-methylpyrrolidone and the like (see Atherton, et al., *J. Am. Chem. Soc.*, 1975, 97, 6584, *Bioorg. Chem.* 1979, 8, 351), and J.C.S. Perkin I 538 (1981)); (2) a second group of solid supports is based on silica-containing particles such as porous glass beads and silica gel. One example is the reaction product of trichloro-[3-(4-
20 chloromethyl)phenyl]propylsilane and porous glass beads (see Parr and Grohmann, *Angew. Chem. Internal. Ed.* 1972, 11, 314) sold under the trademark "PORASIL E" by Waters Associates, Framingham, MA, USA. Similarly, a mono ester of 1,4-dihydroxymethylbenzene and silica (sold under the trademark "BIOPAK" by Waters Associates) has been reported to be useful (see Bayer and Jung, *Tetrahedron Lett.*, 1970, 4503); (3) a third general type of useful solid supports can be
25 termed composites in that they contain two major ingredients: a resin and another material that is also substantially inert to the organic synthesis reaction conditions employed. A preferred support of this type is described in U.S. Patent No. 5,235,028 which is herein incorporated by reference. One exemplary composite (see Scott, et al., *J. Chrom. Sci.*, 1971, 9, 577) utilized glass particles coated with a hydrophobic, cross-linked styrene polymer containing reactive chloromethyl groups,
30 and was supplied by Northgate Laboratories, Inc., of Hamden, CT, USA. Another exemplary composite contains a core of fluorinated ethylene polymer onto which has been grafted polystyrene (see Kent and Merrifield, *Israel J. Chem.* 1978, 17, 243) and van Rietschoten in

- 9 -

"Peptides 1974," Y. Wolman, Ed., Wiley and Sons, New York, 1975, pp. 113-116); and (4) contiguous solid supports other than PEPS, such as cotton sheets (Lebl and Eichler, Peptide Res. 1989, 2, 232) and hydroxypropylacrylate-coated polypropylene membranes (Daniels, et al., Tetrahedron Lett., 1989, 4345), are suited for PNA synthesis as well.

- 5 While the solid-phase technique is presently preferred in the context of PNA synthesis, other methodologies or combinations thereof, for example, in combination with the solid-phase technique, apply as well: (1) the classical solution-phase methods for peptide synthesis (e.g., Bodanszky, "Principles of Peptide Synthesis," Springer-Verlag, Berlin-New York 1984), either by stepwise assembly or by segment/fragment condensation, are of particular relevance when
10 considering especially large scale productions (gram, kilogram, and even tons) of PNA compounds; (2) the so-called "liquid-phase" strategy, which utilizes soluble polymeric supports such as linear polystyrene (Shemyakin, et al., *Tetrahedron Lett.*, 1965, 2323) and polyethylene glycol (PEG) (Mutter and Bayer, *Angew. Chem., Int. Ed. Engl.*, 1974, 13, 88), is useful; (3) random polymerization (see, e.g., Odian, "Principles of Polymerization," McGraw-Hill, New
15 York (1970)) yielding mixtures of many molecular weights ("polydisperse") peptide or PNA molecules are particularly relevant for purposes such as screening for antiviral effects; (4) a technique based on the use of polymer-supported amino acid active esters (Fridkin, et al., *J. Am. Chem. Soc.*, 1965, 87, 4646), sometimes referred to as "inverse Merrifield synthesis" or "polymeric reagent synthesis," offers the advantage of isolation and purification of intermediate
20 products, and may thus provide a particularly suitable method for the synthesis of medium-sized, optionally protected, PNA molecules, that can subsequently be used for fragment condensation into larger PNA molecules; (5) it is envisaged that PNA molecules may be assembled enzymatically by enzymes such as proteases or derivatives thereof with novel specificities (obtained, for example, by artificial means such as protein engineering), and one also can envision
25 the development of "PNA ligases" for the condensation of a number of PNA fragments into very large PNA molecules; and (6) since antibodies can be gernated to virtually any molecule of interest, the recently developed catalytic antibodies (abzymes), discovered simultaneously by the groups of Lerner (Tramantano, et al., *Science*, 1986, 234, 1566) and of Schultz (Pollack, et al.,
Science, 1986, 234, 1570), also should be considered as potential candidates for assembling PNA
30 molecules. There has been considerable success in producing abzymes catalyzing acyl-transfer reactions (see for example Shokat, et al., *Nature*, 1989, 338, 269 and references therein). Finally, completely artificial enzymes, very recently pioneered by Stewart's group (Hahn, et al., *Science*,

- 10 -

1990, 248, 1544), may be developed to suit PNA synthesis. The design of generally applicable enzymes, ligases, and catalytic antibodies, capable of mediating specific coupling reactions, should be more readily achieved for PNA synthesis than for "normal" peptide synthesis since PNA molecules will often be comprised of only four different amino acids (one for each of the four native nucleobases) as compared to the twenty naturally occurring (proteinogenic) amino acids constituting peptides. In conclusion, no single strategy may be wholly suitable for the synthesis of a specific PNA molecule, and therefore, sometimes a combination of methods may work best.

Summary of the Invention

10 Accordingly, it is an object of this invention to provide a convenient high yield synthetic pathway to novel PNA synthons synthons which are compatible with DNA synthetic reagents and instrumentation, and therefore, suitable for synthesis of PNA-DNA chimeras. Another object of this invention is to provide PNA-DNA chimeras. Still another object of this invention is to provide a novel synthetic route to an acid labile protected amino backbone used in the
15 construction of the above PNA synthons.

This invention is a method for a convenient high yield synthesis of novel PNA suitable for synthesis of PNA-DNA chimeras. While the invention will be directed towards PNA-DNA chimeras, a PNA-RNA chimera or other various combinations are equally accessible using the PNA synthons and methodology of this invention. A PNA-DNA chimera is an oligomer that is
20 composed of at least one PNA moiety and at least one DNA moiety. PNA synthons suitable for the synthesis of a PNA-DNA chimera preferably have orthogonal protection compatible with DNA synthesis, i.e., acid labile protection of the reactive group on the backbone and base labile protection of the side chain nucleobase groups. In addition, the PNA synthons preferably will have protecting groups with similar lability to the protecting groups used in DNA synthesis to
25 avoid the use of harsh chemical conditions that decompose DNA. As part of this invention, a novel synthetic process is described for the synthesis of an increased acid labile protected amino backbone used in the construction of the PNA synthons.


Additional features and advantages of the invention will be set forth in the description which follows, and, in part will be apparent from the description, drawings, and claims, or may be
30 learned by practice of this invention.

- 11 -

By the method of this invention, a PNA-DNA chimera is synthesized having the general formula:


KLQMN

The letters K and N represent chemical bonds, such as covalent bonds, and the letter Q represents
5 a linker or a chemical bond. One of L and M is a nucleotide moiety having the formula:




The atom or group represented by G is a secondary nitrogen atom, a tertiary nitrogen atom having an alkyl substituent, an oxygen atom or a sulfur atom. The group represented by B is a protected or unprotected, natural or unnatural nucleobase. The atom or group represented by D is a hydrogen atom, hydroxyl group, a methoxyl group or a hydroxyl group which is protected by a protecting group.
10

The other of L and M is a PNA moiety of the formula:




The groups represented by G and B are as defined above. The atom or group represented by R7
15 is a hydrogen atom or a side chain of a protected or unprotected naturally occurring α amino acid. Each of j, g and h is the same or different and is independently zero or an integer from one to five.

The PNA-DNA chimeras typically are formed from nucleotide moieties having the formula:




- 12 -

and PNA moieties having the formula:



where G, B, D, R⁷, j, g and h are as defined above. The atom or group represented by each of P_n and Pa is a hydrogen atom or a protecting group, with one of P_n or Pa representing a hydrogen atom. The group represented by R⁶ is a protective group which can be removed after oligomer synthesis is complete. The entity L¹ is a leaving group or chemical bond. The entity L² is a hydroxyl group, a leaving group or a chemical bond.

Preferably, R⁶ is a group having the formula:



10 Each of V₁-V₃ is the same or different and is independently selected from hydrogen, methyl or ethyl. The group represented by W is an electron withdrawing group. Preferred electron withdrawing groups include, but are not limited to, cyano, alkyl sulfonyl, aryl sulfonyl, phenyl and substituted phenyl, such as p-nitrophenyl, o-nitrophenyl and p-alkyl sulfonylphenyl.

Preferably, L¹ is a halogen, CN, SCN or a secondary amino group having the formula:

15 -NR⁸R⁹


where each of R⁸ and R⁹ is the same or different and is independently selected from primary, secondary or tertiary alkyl groups having 1-10 carbon atoms, or are together selected from cycloalkyl groups having 5-7 carbon atoms which can contain one or two nitrogen, oxygen or sulfur atoms as heteroatoms.

20 The entity L², if a leaving group, can be an activated ester, other leaving groups such as imidazole, triazole, tetrazole, 3-nitro-1,2,4-triazole, thiazole, pyrrole, benzotriazole, benzohydroxytriazole. These cycloalkyl groups also include imidazole substituted in the phenyl moiety, triazole substituted in the phenyl moiety, tetrazole substituted in the phenyl moiety, 3-nitro-1,2,4-triazole substituted in the phenyl moiety, thiazole substituted in the phenyl moiety,

- 13 -

pyrrole substituted in the phenyl moiety, benzotriazole substituted in the phenyl moiety, or benzohydroxytriazole substituted in the phenyl moiety.

- Examples of nucleobase compounds represented by B are shown in Figure 8. The preferred nucleobases include adenine, cytosine, guanine, thymine, uracil, pseudo isocytosine, 5-methyl cytosine, hypoxanthine, isocytosine, pseudouracil and 2,6-diaminopurine. Generally, nucleobases have exocyclic amino groups which are protected during the synthesis of the nucleic acid oligomer by removable protecting groups (these protected nucleobases are a subset of B and are independently represented by Ba). The generally accepted orthogonal strategy for DNA synthesis dictates that the exocyclic amino groups are protected by base labile protecting groups.
- Base labile protecting groups can include base labile carbamate protecting groups such as an ethoxycarbonyl group having the formula:



- The group represented by W is an electron withdrawing group. The atom or group represented by each of R²-R⁴ is the same or different and is independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl or t-butyl. Preferred electron withdrawing groups include, but are not limited to, cyano, alkyl sulfonyl, aryl sulfonyl, phenyl and substituted phenyl, such as p-nitrophenyl, o-nitrophenyl and p-alkyl sulfonylphenyl.

- As an oligomer is synthesized, often with one end of the oligomeric chain attached to a solid support, the number of nucleotide or PNA moieties in the oligomer chain is increased one by one until the desired sequence is attained. Subsequent nucleotide or PNA moieties having a backbone protecting group are coupled to the previously added moiety on the growing chain. By the method of this invention, the backbone protecting group in the orthogonal strategy is an acid labile protecting group while the nucleobase is protected by a base labile protecting group. Thus, in the case of this invention, the letter K can represent a covalent bond that attaches the nucleic acid oligomer to the next nucleotide or PNA moiety having a backbone protecting group so as to allow reaction at only one site.

- The synthesis of the chimera differs depending on whether Q is a covalent bond or a linker used to connect the PNA and nucleotide moieties. When a linker is used, the linker is first attached to the terminal PNA or nucleotide moiety followed by a typical coupling cycle. A linker may be used to provide more stable linkages, provide a spacer to optimize the hybridization

- 14 -

properties of the chimera, impart a special property on the chimera such as to invert polarity or merely for convenience.

Regardless whether a linker is used, the assembly of the chimera generally involves synthesis cycles of a deprotection step followed by a coupling step. When nucleotide moieties are involved, oxidation of the phosphorus atom is an additional required step in the cycle. In addition, when coupling nucleotide moieties to a heteroatom, it is preferable to avoid a nitrogen heteroatom because the resulting nitrogen-phosphorus bond is acid sensitive. Since the linkers usually have a readily accessible functional group and a second protected reactive group, the same synthetic cycle is often utilized. However, many manipulations of DNA and polypeptide-like 10 moieties are well known and are suitable for introducing specific reactive functional groups onto an oligomer without adhering to the synthetic cycle outlined above.

Generally, when Q is a covalent bond, the synthesis cycle will involve providing a PNA or nucleotide moiety where L¹ or L² is a covalent bond, removing the Pa or Pn protecting group to generate a hydrogen atom on the heteroatom G, providing a PNA or nucleotide moiety having a 15 Pn or Pa protecting group different from the group just removed, and coupling this later moiety to the deprotected heteroatom G of the PNA or nucleotide moiety where L¹ or L² is a covalent bond.


On the other hand, when Q is a linker, the synthesis cycle will involve providing a PNA or nucleotide moiety where L¹ or L² is a covalent bond, removing the Pa or Pn protecting group to 20 generate a hydrogen atom on the heteroatom G, generating a linker containing a reactive heteroatom by reaction with the heteroatom G, providing a PNA or nucleotide moiety having a Pn or Pa protecting group different from the group just removed, and coupling this later moiety to the heteroatom of the linker.

Typically, at the end of the synthesis, when the desired oligomer is attained, removal of all 25 protecting groups occurs, i.e., removal of whichever of Pn or Pa is not hydrogen and removal of the base labile protecting groups of the nucleobases. If the oligomer was synthesized using a solid support, cleavage of the oligomer from the solid support also occurs. Because solid phase synthesis is preferred, this invention also relates to support bound PNA-DNA chimeras.

PNA-DNA chimeras of this invention may contain a detectable moiety. Examples of 30 detectable moieties include, but are not limited to, enzymes, antigens, radioactive labels, affinity labels, fluorescent labels, ultraviolet labels, infrared labels and spin labels.


- 15 -

Another aspect of this invention is directed to PNA synthons having the formula:




wherein G, R⁷, j, g, and h are defined above. The group represented by Pg is an acid labile protecting group. The group represented by Ba is a natural or unnatural nucleobase having an exocyclic amino group protected by a base labile amino protecting group. Examples of Ba include, but are not limited to, adenine, cytosine, guanine, pseudo isocytosine, 5-methyl cytosine, isocytosine and 2,6-diaminopurine. In a preferred embodiment, G is a secondary nitrogen atom. In other preferred embodiments, Pg and the base labile amino protecting group are independently carbamate protecting groups.

In another aspect, this invention is directed to PNA synthons having the formula:



wherein Pg and Ba are as defined above.

Preferred embodiments of the compounds occur when Pg is a carbamate protecting group and specifically the carbamate protecting group having the formula:




The atom or group represented by each of A₁-A₁₀ is the same or different and is independently hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, hydroxy, methoxy, ethoxy, amide or ester groups. The ester group includes an activated ester. The atom or group represented by R⁴ is hydrogen, methyl or ethyl. The most preferred embodiment occurs when Pg is 4,4'-dimethylbenzhydroxycarbonyl.

- 16 -


Preferred embodiments of the above compounds occur when Ba is adenine, cytosine, guanine, pseudo isocytosine, 5-methyl cytosine, isocytosine or 2,6-diaminopurine. Preferred embodiments also occur when Ba is protected by a carbamate base labile protecting group having the formula:

5




where W and R²-R⁴ are as defined above.

The carbamate base labile protecting group also can be 9-fluorenylmethyloxycarbonyl or a 1-cyanoethoxycarbonyl group having the formula:




10 where R²-R⁴ are as defined above. A preferred embodiment occurs when R² is a hydrogen atom and R³ and R⁴ are each methyl groups.

In another embodiment, the carbamate base labile protecting group can be a sulfoethoxycarbonyl group having the formula:



15 where R²-R⁴ are as defined above. The letter n is the integer one or two. The group represented by R⁵ is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, or a substituted or unsubstituted phenyl group. The substituted or unsubstituted phenyl group has the formula:




20 where the atom or group represented by each of a-e is the same or different and is independently selected from F, Cl, Br, I, hydrogen, methyl, ethyl, isopropyl, n-propyl, n-butyl, t-butyl, phenyl, methoxy, ethoxy, -NO₂, -CN, -SO₃H, -SCH₃ or -(O)SCH₃. Preferred embodiments occur when


- 17 -

R^5 is methyl, n is two and R^2-R^4 are each hydrogen; and when R^5 is an unsubstituted phenyl, n is two and R^2-R^4 are each hydrogen.


A preferred embodiment of the invention is an adenine PNA synthon having the formula:



5 A preferred embodiment of the invention is a cytosine PNA synthon having the formula:




A preferred embodiment of the invention is a guanine PNA synthon having the formula:



- 18 -


where n is one or two.

Another preferred embodiment of the invention is a guanine PNA synthon having the formula:




5 where n is one or two.

A preferred embodiment of the invention is a thymine PNA synthon having the formula:



- 19 -

A preferred embodiment of the invention is a pseudo isocytosine PNA synthon having the formula:




In another aspect, the invention is directed to PNA oligomers having the general formula:

5

KLQMN


where K, Q and N are as previously defined. Each of L and M are PNA moieties having the formula:



where G, B, R⁷, g, h and j are as previously defined.

10

Another aspect of the invention is directed to an acid labile protected backbone having the general formula:




The group represented by Pg is an acid labile protecting group. The atom represented by G is a secondary nitrogen atom, a tertiary nitrogen atom having an alkyl substituent, an oxygen atom or a sulfur atom. The entity R⁷ is a hydrogen atom or a side chain of a naturally occurring α amino

- 20 -

acid. The letters g and h are the same or different and are independently zero or an integer from one to five.


A preferred acid labile protected backbone is an acid labile amino protected backbone having the general formula:

5



The group represented by R⁷ is hydrogen or a side chain of a protected or unprotected naturally occurring α amino acid. Each of the letters g and h is the same or different and is independently zero or an integer from one to five. Preferably, the group represented by Pg is an acid labile protecting group having the formula:

10



15 are each hydrogen atoms; g is one; h is zero; and R⁷ is hydrogen.

Generally, the method of synthesizing the preferred acid labile amino protected backbone involves the coupling of an alcohol, e.g., a benzhydrol derivative, to a diamine utilizing a carbonyl equivalent thereby forming a carbamate protecting group on one of the amino groups. After formation of the carbamate protecting group, an unreacted primary amino group of the diamine is 20 converted to an acetamide derivative which subsequently is transformed into an alkyl carboxy group. Other embodiments of the acid labile protected backbone which include a sulfur atom or oxygen atom as the heteroatom G can be prepared utilizing the above synthetic methodology.

In another aspect, the invention is directed to the end use of the PNA-DNA chimeras. PNAs exhibit a stronger binding affinity with DNA under defined conditions which can be

- 21 -

exploited for many purposes. Likewise, PNA-DNA chimeras have the potential to exhibit greater binding affinity with DNA which increases the potential uses of this unique synthetic polymer. Examples of the utility of PNA-DNA chimeras include, but are not limited to, therapeutic or antisense agents, primers in polymerase reactions and probes for the detection of genetic materials or sequences.

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. The invention will be understood further from the following drawings, which are incorporated in and constitute a part of this specification.

10 Brief Description of the Drawings

Figure 1 is a schematic representation of the synthesis of the preferred acid labile protected amino backbone of the amino acid N-(2-aminoethyl)-glycine of this invention.

Figure 2 is a schematic representation of the synthesis of the preferred carbamate protected cytosine side chain moiety of this invention.

15 Figure 3 is a schematic representation of the synthesis of the preferred carbamate protected adenine side chain moiety of this invention.

Figure 4 is a schematic representation of the synthesis of the preferred carbamate protected guanine side chain moiety of this invention.

20 Figure 5 is a schematic representation of the synthesis of a preferred reagent of this invention for the formation of a carbamate protecting group.

Figure 6 is a schematic representation of the coupling of the preferred acid labile protected amino backbone of the amino acid N-(2-aminoethyl)-glycine to the preferred nucleobase side chain moieties to form the preferred PNA synthons of this invention. The nucleobases adenine, cytosine, guanine and thymine are shown.

- 22 -

Figure 7 is a schematic representation of the oxidation of the preferred guanine PNA synthon creating the preferred orthogonally protected guanine PNA synthon of this invention suitable for PNA-DNA chimera synthesis.

5 Figure 8 is a chart illustrating the structural representations of natural and unnatural nucleobases useful in this invention.

Figure 9 is an HPLC trace of the PNA oligomer sequence $\text{H}_2\text{N}-\text{CTTCTCC}-\text{CONH}_2$.

Figure 10 is an HPLC trace of the PNA oligomer sequence $\text{H}_2\text{N}-\text{CGCTATAACC}-\text{CONH}_2$.

10 Figure 11 is an HPLC trace of the unpurified PNA-DNA chimera sequence DMBhoc-HN-
CACAC-CONH-linker-5'-CCAGT-3'-OH. The underlined portion of the sequence represents
the PNA sequence and the bold portion of the sequence represents the DNA sequence. DMBhoc
is 4,4'-dimethylbenzhydroxycarbonyl.

15 Figure 12 is an HPLC trace of the purified PNA-DNA chimera sequence DMBhoc-HN-
CACAC-CONH-linker-5'-CCAGT-3'-OH. The underlined portion of the sequence represents
the PNA sequence and the bold portion of the sequence represents the DNA sequence. DMBhoc
is 4,4'-dimethylbenzhydroxycarbonyl.

20 Figure 13 is an HPLC trace of the PNA-DNA chimera sequence (gradient only) DMBhoc-
HN-CACAC-CONH-linker-5'-CCAGT-3'-OH. The underlined portion of the sequence
represents the PNA sequence and the bold portion of the sequence represents the DNA sequence.
DMBhoc is 4,4'-dimethylbenzhydroxycarbonyl.

Detailed Description of the Invention

The applicant has developed a convenient high yield method for preparing novel PNA synthons suitable of the synthesis of PNA-DNA chimeras, which are oligomers composed of at least one PNA moiety and at least one DNA moiety. Generally, the PNA synthons have
25 orthogonal protection which is compatible with DNA synthesis, i.e., protecting groups capable of

- 23 -

removal under mild conditions that will not substantially decompose DNA and having base labile protection of the nucleobase and acid labile protection of the backbone moiety.

First, the acid labile protected backbone of the PNA synthon is synthesized. Preferably, the acid labile protecting group should have similar lability to the most common DNA backbone protecting group, dimethoxytrityl (DMT), the applicants have developed a new synthetic pathway to a preferred acid sensitive backbone.

Second, the nucleobase side chain moiety having base labile protection of the exocyclic amino groups is synthesized. Either natural or unnatural nucleobases can be incorporated into the PNA synthons.


Third, the acid labile protected backbone is coupled to the nucleobase side chain moiety which has base labile protection of the exocyclic amino group, if present. The coupling reaction results in PNA synthons suitable for the synthesis of PNA-DNA chimeras, as well as PNA-RNA chimeras and various other combinations. The PNA synthons of this invention also can be used for the synthesis of PNA oligomers under very mild conditions, unlike those currently utilized.

Finally, the PNA synthons of this invention are used in the synthesis of PNA-DNA chimeras, demonstrating their utility with commercially available DNA nucleotides. While the description focuses on PNA-DNA chimeras, the PNA synthons and methodologies of this invention are equally applicable to PNA-RNA chimeras and various other combinations.

Acid Labile Protected Backbone Synthesis

In one embodiment, the invention is a method for the preparation of an acid labile protected backbone of a PNA synthon. The preferred backbone is an acid labile amino protected backbone (see Figure 1). The acid labile protecting group is capable of removal under mild conditions that will not substantially decompose DNA moieties. Therefore, when the acid labile backbone is attached to the nucleobase side chain moiety, the resulting PNA synthon is suitable for PNA-DNA chimera synthesis.


The acid labile protected backbone has the general formula:



- 24 -

- The group represented by Pg is an acid labile protecting group. The atom represented by G is a secondary nitrogen atom, a tertiary nitrogen atom having an alkyl substituent, an oxygen atom or a sulfur atom. The entity R⁷ is a hydrogen atom or a side chain of a protected or unprotected naturally occurring α amino acid. The letters g and h are the same or different and are
- 5 independently zero or an integer from one to five.

A preferred acid labile protected backbone is an acid labile amino protected backbone having the formula:




- The entities represented by Pg, R⁷, g and h are as defined above. Although the synthesis of the
- 10 preferred acid labile amino protected backbone is discussed below, other embodiments of the acid labile protected backbone including, but not limited to, an oxygen atom or sulfur atom as G are equally accessible by the general synthetic methodology disclosed in this invention.

Step 1

- The first step in the synthesis of the acid labile protected backbone is the selection of the
- 15 appropriate alcohol that will be incorporated into the protecting group. The alcohol may be commercially available or may be synthetically prepared. The lability of the protecting group will depend on the stability and ease of formation of the cation of the dehydrated alcohol in an acidic solution. This information is well known for many alcohols and is readily available to those skilled in the art. See Sieber et al., Helv. Chemica Acta (1968) 51:614-22.

- 20 Examples of alcohols that will provide the required acid lability are, among others, benzhydrol derivatives having the formula:



- Each of A₁-A₁₀ is the same or different and is independently hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, hydroxy, methoxy, ethoxy, amide, ester or activated ester groups. The
- 25 atom or group represented by R⁴ is hydrogen, methyl or ethyl.. The atom or group represented


- 25 -

by R⁴ is hydrogen, methyl or ethyl. Alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl. Alkoxy groups include, but are not limited to, methoxy and ethoxy. The preferred embodiment occurs when R⁴ is a hydrogen atom, A₃ and A₈ are each methyl groups, and A₁, A₂, A₄-A₇, A₉ and A₁₀ are each hydrogen atoms.

- 5 With reference to Figure 1, the preferred alcohol is synthesized via a Grignard reaction. First, the magnesium salt of 4-bromotoluene, the Grignard reagent, is prepared in an anhydrous non-nucleophilic ether-based solvent. Examples of suitable solvents include, but are not limited to, diethyl ether, diisopropylether, dioxane and tetrahydrofuran. The preferred solvent is tetrahydrofuran. After preparation of the Grignard reagent, para-tolualdehyde was added to the
 10 room temperature solution of the magnesium salt at a rate sufficient to create a reflux. A sufficient time was allowed for the addition of the Grignard reagent to the aldehyde derivative, then the reaction was quenched with a proton source. Following work up of the reaction mixture, 4,4'-dimethylbenzhydrol is isolated (compound I).


Step 2

- 15 In a preferred embodiment, the appropriately selected alcohol is converted into a corresponding acid labile amino protected diamine having the general formula:



- The group represented by Pg is an acid labile protecting group. The letter g is the integer zero or an integer from one to five. Following the synthetic methodology described below, Pg necessarily
 20 is a carbamate protecting group.

Generally, the alcohol is reacted with a carbonyl equivalent followed by reaction with a diamine of the formula:



- The letter g is zero or an integer from one to five. Examples of carbonyl equivalents include, but
 25 are not limited to phosgene, phosgene derivatives, carbonyldiimidazole and di-N-succinimidyl carbonate..


- With reference to Figure 1, the preferred carbonyl equivalent is carbonyldiimidazole (CDI). The preferred diamine occurs when g is one, i.e., is ethylene diamine. Thus, 4,4'-dimethylbenzhydrol is added to a solution of CDI in an anhydrous non-nucleophilic solvent at
 30 about 0°C. Examples of anhydrous non-nucleophilic solvents are diethyl ether, diisopropylether,

- 26 -

dioxane, tetrahydrofuran, acetonitrile, dichloromethane, chloroform, carbon tetrachloride, benzene and toluene. The preferred solvent is dichloromethane. After the reaction is allowed to occur for a sufficient time, which may be monitored by thin layer chromatography (tlc), the reaction mixture is washed with water, dried, and the dichloromethane evaporated to yield a solid.

5 The solid is redissolved in an anhydrous non-nucleophilic solvent as previously described. Dichloromethane is the preferred solvent. The dichloromethane solution of the solid is added to the amino backbone moiety, ethylene diamine, stirring at about 0°C. After the reaction is complete, the reaction mixture is washed with water, dried and N-(4,4'-dimethylbenzhydroxycarbonyl)-ethylenediamine is isolated (compound II). Thus, the preferred


10 acid labile amino protected diamine has the formula:



II

Step 3

In a preferred embodiment, following formation of the acid labile amino protected diamine, the remaining primary amino group of the diamine is converted into an acetamide derivative producing a fully protected diamine compound having the general formula:



The entities Pg and g are as defined above. The atom represented by X is an electronegative atom or group. Examples of electronegative atoms include, but are not limited to, halogen atoms such as fluorine, chlorine, bromine and iodine.


20 Generally, the acid labile amino protected diamine is reacted with an alkyl trihaloacetate to produce the fully protected diamine compound. Preferably, a non-nucleophilic base is added to neutralize any acid formed by the decomposition of the alkyl trihaloacetate. Examples of non-nucleophilic bases include, but are not limited to, triethylamine, diisopropylamine, N-methyl morpholine and N-ethyl morpholine. The preferred non-nucleophilic base is triethylamine.

25 Among the various examples of alkyl trihaloacetate derivatives, which may include, but are not

- 27 -

limited to, methyl and ethyl esters, ethyltrifluoracetate is preferred. Accordingly, the preferred atom represented by X is fluorine.

Therefore, the preferred fully protected diamine is prepared by reaction of compound II with ethyl trifluoracetate in dichloromethane at about 0°C in the presence of triethylamine (see 5 Figure 1). The product isolated from this reaction is N-[N'-4,4'-dimethylbenzhydrolloxycarbonyl-(2'-aminoethyl)]glycine which has the formula:



Step 4


The final step in the preparation of the acid labile amino protected backbone is the 10 conversion of the acetamide functionality into an alkyl carboxy group. Since the acetamide functionality contains the electron withdrawing trihalo substituent, the secondary nitrogen proton contained in the acetamide functionality is susceptible to removal by a base to produce a nucleophilic nitrogen anion. Examples of bases useful for this transformation include, but are not limited to, lithium hydride, sodium hydride and potassium hydride. The preferred base is sodium 15 hydride.

Following removal of the secondary nitrogen proton, an alkyl haloalkylate is added and the reaction mixture allowed to stir until the reaction is complete. Examples of alkyl haloalkylates, among others, are methyl chloroacetate, ethyl chloroacetate, methyl bromoacetate, ethyl bromoacetate, methyl iodoacetate, ethyl iodoacetate, methyl 3-chloropropionate, ethyl 3-20 chloropropionate, methyl 3-bromopropionate, ethyl 3-bromopropionate, methyl 3-iodopropionate and ethyl 3-iodopropionate. The preferred compound is ethyl bromoacetate. Additionally, the alkyl haloalkylate may be substituted at the halo containing carbon atom with a side chain of a protected or unprotected naturally occurring α amino acid.


A crude intermediate product is isolated, then treated with a hydroxide ion source. 25 Examples of hydroxide ion sources include, but are not limited to, lithium hydroxide, sodium hydroxide and potassium hydroxide. The preferred hydroxide ion source is lithium hydroxide.

- 28 -

Subsequent to work-up, an acid labile amino protected backbone is isolated having the general formula:




The entities Pg and g are as defined above. The letter h is zero or an integer from one to five and
 5 R⁷ is hydrogen or a side chain of a protected or unprotected naturally occurring α amino acids.
 With reference to Figure 1, the preferred acid labile amino protected backbone has the formula:



Nucleobase Side Chain Moiety Synthesis

In another embodiment, the invention is directed to the synthesis of nucleobase side chain
 10 moieties for coupling to the acid labile amino protected backbone (see Figures 2-5).

Since the PNA synthons of this invention are orthogonally protected, the exocyclic amino groups of the nucleobase side chain moieties necessarily are not protected with acid labile protecting groups. Examples of possible protecting groups include, but are not limited to, those that are cleaved by basic conditions, photolytic conditions or hydrogenolysis conditions. The
 15 preferred nucleobase protecting groups are base labile. Generally, the novel nucleobase side chain moieties have the general formula:




The letter j is zero or an integer from one to five. The entity Ba is a natural or unnatural
 20 nucleobase having an exocyclic amino group protected by a base labile protecting group (as described above, Ba is a subset of B). Examples of natural nucleobases having an exocyclic

- 29 -

amino group are adenine, cytosine and guanine. Examples of unnatural nucleobases having an exocyclic amino group include, but are not limited to, pseudo isocytosine, 5-methyl cytosine, isocytosine and 2,6-diaminopurine.

- Examples of base labile amino protecting groups include, but are not limited to, 9-
5 fluorenylmethyloxycarbonyl (Fmoc) and ethoxycarbonyl groups having the general formula:




The group represented by W is an electron withdrawing group. The atom or group represented by each of R²-R⁴ is the same or different and is independently hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl or t-butyl.

- 10 The novel nucleobase side chain moieties of this invention can be synthesized via a novel isocyanate method, as disclosed in a companion patent application entitled "Improved Synthons for the Synthesis and Deprotection of Peptide Nucleic Acids Under Mild Conditions" (Attorney Docket No. SYP-091; U.S. Application Serial No. _____, filed June 7, 1995) which is herein specifically incorporated by reference in its entirety. Alternatively, the nucleobase side chain
15 moieties can be synthesized by conventional methods which involve protection of the exocyclic amino groups of the nucleobase with imidazolides or alkyl imidazolium salts.

Step 1

- In both of the above synthetic schemes, a nucleobase is first transformed into a partially protected nucleobase compound having an alkyl formate substituent, an alkyl acetate substituent
20 or an alkyl ester substituent such as an alkyl propionate, an alkyl butanoate, an alkyl pentanoate or an alkyl hexanoate. Thus, the partially protected nucleobase compound has the formula:




- The letter j is zero or an integer from one to five. The entity B is the nucleobase having an exocyclic amino group. The group represented by R¹⁰ is methyl, ethyl, 2,2,2-trichloroethyl, 2-
25 (trimethylsilyl)-ethyl, 2-(phenylthio)-ethyl, propyl, isopropyl, n-butyl, t-butyl, allyl, 1-isopropyl allyl, cinnamyl, 4-nitrocinnamyl, or a substituted or unsubstituted benzyl.


- 30 -

Generally, sequential treatment of the nucleobase with a base such as potassium carbonate or potassium t-butoxide and an alkyl haloalkylate produces the partially protected nucleobase compound. An alkyl or benzyl bromoacetate produces the preferred partially protected nucleobase compounds.

- 5 With reference to Figure 2, the preferred partially protected cytosine compound has the formula:




With reference to Figure 3, the preferred partially protected adenine compound has the formula:



10


With reference to Figure 4, the preferred partially protected guanine precursor compound has the formula:



Step 2


- 15 The partially protected nucleobase compound is transformed into a fully protected nucleobase compound by protecting the exocyclic amino group of the nucleobase with a base labile protecting group. The fully protected base labile protected compound has the general formula:

- 31 -




The letter j is as previously defined. The groups represented by Ba and R¹⁰ are as previously defined. The base labile protecting group can be formed by either the isocyanate method as referenced above, e.g., as with the partially protected guanine compound, or by conventional methods, e.g., as with the partially protected adenine and cytosine compounds.

5 Examples of base labile amino protecting groups include, but are not limited to, 9-fluorenylmethyloxycarbonyl (Fmoc) and ethoxycarbonyl groups having the general formula:



The group represented by W is an electron withdrawing group. The atom or group represented
10 by each of R²-R⁴ is the same or different and is independently hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl or t-butyl.

Examples of electron withdrawing groups are, among others, cyano, alkyl sulfonyl, aryl sulfonyl, phenyl and substituted phenyl such as p-nitrophenyl, o-nitrophenyl and p-alkyl sulfonyl phenyl. With CN as the electron withdrawing group, the base labile protecting group has the
15 formula:




The atom or group represented by each of R²-R⁴ is the same or different and is independently hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl or t-butyl.

The preferred method of preparing the 1-cyanoethoxycarbonyl group is by reaction of the
20 corresponding 1-cyanoethanol derivative with carbonyldimidazole to form the imidazolide salt. The preferred 1-cyanoethanol derivative is 2-hydroxy-2-methyl-butyronitrile. Thus, in reference to Figure 5a, reaction of 2-hydroxy-2-methyl-butyronitrile with carbonyldiimidazole produces compound XIV, 2,2-dimethyl-1-cyanoethoxycarbonyl-imidazole.


- 32 -

To enhance the acylating efficiency of this preferred reagent, 2,2-dimethyl-1-cyanoethoxycarbonyl-imidazole is reacted with methyl trifluoromethanesulfonate to produce compound XV (see Figure 5b). Preferably, the reagent is generated in situ immediately before reaction with the partially protected nucleobase compound.

- 5 Thus, with reference to Figure 2, the preferred fully protected cytosine compound has the formula:




With reference to Figure 3, the preferred fully protected adenine compound has the formula:



10


With a sulfoxide or sulfone as the electron withdrawing group, the fully protected nucleobase compound is typically formed via the isocyanate method and has the formula:



- 15 The letter n is one or two. The atom or group represented by each of R²-R⁴ is the same or different and is independently hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl or t-butyl.

- 33 -


The group represented by R⁵ is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl or a substituted or unsubstituted phenyl having the formula:



- The atom or group represented by each of a-e is the same or different and is independently F, Cl, 5 Br, I, hydrogen, methyl, ethyl, isopropyl, n-propyl, n-butyl, t-butyl, phenyl, methoxy, ethoxy, NO₂, -CN, -SO₃H, -SCH₃ or -(O)SCH₃.

- Of special note, in the case of guanine, the exocyclic amino group of 2-amino-6-chloropurine is first protected as a thioether group, i.e., an unoxidized sulfur (see Figure 4, compound XII). Although not a base labile protecting group, the thioether group avoids 10 premature base elimination of the sulfur containing protecting group since preparation of the carbamate protected guanine side chain moiety (compound XIII) requires treatment with strong base. Only after coupling to the acid labile amino protected backbone is the sulfur atom oxidized to form the base labile protecting group.

- Thus, with reference to Figure 4, the preferred fully protected guanine precursor 15 compound has the formula:




Step 3

- Generally, the acetate ester group of the fully protected nucleobase compound is hydrolyzed with acid to produce the nucleobase side chain moiety. In the case of the fully 20 protected guanine compound, hydrolysis is contemporaneous with formation of the C6 carbonyl group as described in "Improved Synthons for the Synthesis and Deprotection of Peptide Nucleic Acids Under Mild Conditions" (Attorney Docket No. SYP-091; U.S. Application Serial No. _____, filed June 7, 1995) (see Figure 4 of this application).


- 34 -

With reference to Figure 2, the preferred cytosine side chain moiety has the formula:




VII

With reference to Figure 3, the preferred adenine side chain moiety has the formula:



X

5 With reference to Figure 4, the preferred guanine side chain moiety has the formula:



XIII


Other nucleobase side chain moieties include a thymine side chain moiety and an uracil side chain moiety. Both of these nucleobases lack exocyclic amino groups, therefore, do not require the additional protection steps. However, the thymine side chain moiety and the uracil
10 side chain moiety can be coupled to the acid labile amino protected backbone to form novel PNA synthons.

- 35 -

PNA Synthon Synthesis ("The Coupling Step")

In another embodiment, the invention is a method for the preparation of PNA synthons suitable for PNA-DNA chimera synthesis (see Figure 6). The preparation of a guanine PNA synthon having a thioether group protecting the exocyclic amino group of guanine involves the 5 oxidation of the thioether group to a sulfoxide or sulfone derivative (see Figure 7). The resultant sulfoxide or sulfone transforms the thioether protecting group into a base labile protecting group, thus creating an orthogonally protected guanine PNA synthon.

Coupling of an acid labile protected backbone to the nucleobase side chain moiety produces a PNA synthon having the formula:



10

The entities Pg, Ba, R⁷, g, h and j are as previously defined. The group represented by G is a secondary nitrogen atom, a tertiary nitrogen atom having an alkyl substituent, an oxygen atom or a sulfur atom.

Because the PNA synthon is orthogonally protected, i.e., typically one acid labile 15 protecting group and one base labile protecting group, the method of coupling the two moieties together preferably minimizes the conditions that will remove either of the two protecting groups. Previously described coupling methods often used the carboxylic ester of a protected backbone, then hydrolyzed the ester with a hydroxide ion source. The basic hydrolysis conditions are unsuitable for the PNA synthons of this invention as the base labile protecting group of the 20 nucleobases would be at least partially removed. Therefore, the preferred method of coupling the nucleobase side chain moiety to the acid labile protected backbone involves "transient" protection of the carboxylic acid functionality of the protected backbone.

Generally, the coupling method involves addition of a silyl carboxylic acid protected acid 25 labile protected backbone to a solution of a preformed mixed anhydride of the nucleobase side chain moiety. Following coupling of the backbone and the side chain moiety, the silyl protecting group is removed to produce the PNA synthon.


- 36 -

More specifically, the mixed anhydride of the nucleobase side chain moiety is formed by treatment of the nucleobase side chain moiety with a non-nucleophilic base at below ambient temperature, followed by reaction with a alkyl acid chloride. Non-nucleophilic bases useful in this step of the reaction sequence include, but are not limited to, triethylamine, diisopropylethylamine,

- 5 N-methyl morpholine and N-ethyl morpholine. The preferred non-nucleophilic base is N-methyl morpholine. Typically the reaction is stirred at below ambient temperature, preferably about 0°C, for a sufficient time to allow formation of the mixed anhydride, which may be monitored by tlc.


Following formation of the mixed anhydride, a solution of the acid labile protected backbone in the presence of a non-nucleophilic base and a sterically hindered silyl chloride is
 10 added to the cooled mixed anhydride solution. Typically, the solution of the acid labile amino protected backbone also is below ambient temperature, preferable about 0°C. Examples of non-nucleophilic bases are those previously described. A preferred sterically hindered silyl chloride is triisopropylsilyl chloride, however, other silyl chlorides can be used. After the reaction is stirred for a sufficient time to allow coupling, the reaction is quenched, dried and then subjected to
 15 treatment with a silyl removing group in the presence of a non-nucleophilic base. Again, examples of non-nucleophilic bases are those previously described. Examples of silyl removing groups include, but are not limited to, hydrogen fluoride, tetra-n-butyl ammonium fluoride and triethylamine trihydrofluoride. The preferred silyl removing group is triethylamine trihydrofluoride because the pH of the solution can be adjusted, thereby minimizing premature
 20 removal of other protecting groups. Subsequent to removal of the silyl protecting group and work-up of the reaction, the desired PNA synthon is isolated.

Thus, in one embodiment, a preferred PNA synthon has the formula:




The groups Pg and Ba are as previously defined.

- 25 In another embodiment, a preferred PNA synthon has the formula:




- 37 -

The group represented by B is as previously defined. The group represented by Pg is an acid labile protecting group of the formula:




Each of A₁-A₁₀ is the same or different and is independently hydrogen, methyl, ethyl, n-propyl,
5 isopropyl, n-butyl, t-butyl, hydroxy, methoxy, ethoxy, amide or ester groups. The atom or group
represented by R⁴ is hydrogen, methyl or ethyl.

In another embodiment, the preferred cytosine PNA synthon has the formula:



XVI


In another embodiment, the preferred adenine PNA synthon has the formula:



XVII


- 38 -

In another embodiment, a preferred guanine PNA synthon has the formula:




The group represented by R⁵ is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl or a substituted or unsubstituted phenyl group having the formula:

5



where the atom or group represented by each of a-e is the same or different and is independently F, Cl, Br, I, hydrogen, methyl, ethyl, isopropyl, n-propyl, n-butyl, t-butyl, phenyl, methoxy, ethoxy, -NO₂, -CN, -SO₃H, -SCH₃ or -(O)SCH₃. It should be noted that the guanine PNA synthon can be oxidized to generate the base labile protecting group before or after incorporation 10 into an oligomer.


In another embodiment, the preferred thymine PNA synthon has the formula:



XIX

- 39 -


In another embodiment, the preferred pseudo isocytosine PNA synthon has the formula:



To complete the synthesis of a preferred guanine PNA synthon having a thioether containing protecting group, oxidation of the thioether group remains. Methods of oxidizing a sulfur atom to a sulfoxide or to a fully oxidized sulfone are known to those skilled in the art.

5 Tesser et al., Int. J. Peptide Protein Res. (1975) 7:295-305. For example, a preferred method involves the sequential treatment of the guanine synthon (compound XVIII) in an aqueous solvent with a non-nucleophilic base, sodium tungstate, and hydrogen peroxide (see Figure 7). Typically the reaction is monitored for completeness by tlc or high performance liquid chromatography


10 (HPLC). After the reaction is complete, work-up and isolation of the product produces the preferred guanine PNA synthon having the formula:



XX


- 40 -

Thus, in one embodiment, a preferred guanine PNA synthon has the formula:



The letter n is one or two.

In another embodiment, a preferred guanine PNA synthon has the formula:



5

The letter n is one or two.

PNA-DNA Chimera or PNA Oligomer Synthesis


In another embodiment, the invention is a method for the preparation of a PNA-DNA chimera or a PNA oligomer. Typically, for the efficient synthesis of these nucleic acid polymers, 10 mild reaction conditions are required and an orthogonal protecting group strategy is used. Therefore, the PNA synthons of this invention are particularly advantageous because their protecting groups are removed under mild conditions and are orthogonal when two protecting groups are required. Moreover, the protection methodology is compatible with commercial DNA synthesis technology.

- 41 -

Generally, the PNA-DNA chimera (or a PNA-RNA chimera and various combinations thereof) will have the formula:


KLQMN

The letters K and N represent chemical bonds. The letter Q is a chemical bond or a linker. One of L and M is a nucleotide moiety having the formula:



The atom represented by G is a secondary nitrogen atom, a tertiary nitrogen atom having an alkyl substituent, an oxygen atom or a sulfur atom. The entity B is a protected or unprotected, natural or unnatural nucleobase. The atom or group represented by D is a hydrogen atom, a hydroxyl group, a methoxyl group or a hydroxyl group which is protected by a protecting group.

10 The other of L and M is a PNA moiety having the formula:



The entities G and B are as defined above. The entity R⁷ is a hydrogen atom or a side chain of a protected or unprotected naturally occurring α amino acid. Each of j, g and h is the same or different and is independently zero or an integer from one to five.

15 The chemical bond defined by K and N can be a covalent bond or an ionic bond. The chemical bond can attach a PNA moiety or a nucleotide moiety to another PNA moiety or nucleotide moiety, either as a single species or as part of a polymeric chain. The chemical bonds also can attach linkers, linkers coupled to a solid support, or other chemical entities. Examples of 20 chemical entities include, but are not limited to, protecting groups, hydrogen atoms, alkyl groups and aryl groups as only a few examples. Examples of solid supports include, but are not limited to, controlled pore glass, membranes, beaded polystyrene, silica gel, silica, paper filters and fritted glass. One of skill in the art will be able to further identify and expand the possibilities of other chemical entities, supports and bonds that would be appropriate and useful in this invention.

- 42 -

Where Q represents a chemical bond, a covalent bond is intended. As with K and N, the chemical bond can attach a PNA moiety or a nucleotide moiety to another PNA moiety or nucleotide moiety, either as a single species or as part of a polymeric chain. The entity Q also can represent a linker which connects the PNA moiety and the nucleotide moiety.

5 Linkers are well known in the field of DNA and peptide synthesis. For a detailed discussion, see U.S. Patent No. 5,410,068 which is herein incorporated by reference and Gati, M.J., Oligonucleotide Synthesis, A Practical Approach, IRL Press Inc., Oxford, England. As used herein, a linker is a composition which can be used for attachment of a moiety to a biopolymer. The moiety may be a support, a biomolecule such as an amino acid or nucleotide or
10 a label such as a fluorescent dye. As used herein, the linker Q is used to modify the heteroatom G of the PNA or nucleotide moiety.

One type of linker comprises a phosphoramidite linker which typically is used to label the terminus of a synthetic oligonucleotide. The linker comprises a reactive phosphoramidite group a spacer and at least one protected heteroatom. Examples of such preformed DNA linkers include
15 those described in the following references. Nelson et al., Nucleic Acid Research, (1989) 17, 7170; Misiura et al, Nucleic Acids Research (1990) 18, 4345; Connelly, B., Nucleic Acids Research (1987) 15, 3131; Coull et al., Tetrahedron Letters (1986) 27, 3991. The spacer is generally an alkyl spacer having 1-12 carbon atoms. The protecting group of the heteroatom is chosen to be compatible with DNA synthesis. Linkers of this type are generally commercially
20 available from suppliers of DNA synthesis reagents.

The 5'-terminus of an oligonucleotide likewise can be modified by known methods. This method is likewise suitable for modifying the terminus of a PNA. See Wachter et al., Nucleic Acids Res. (1986) 14:7985. Generally the heteroatom of the terminus is reacted sequentially with carbonyldiimidazole and then with an amine containing compound of choice. The amine
25 containing compound for the purposes of chimera synthesis will preferably include alkyl diamines, amino alkane thiols and amino alkyl alcohols having 1-12 carbons. Suitable reagents are available from Aldrich Chemical. Using the above referenced reagents and methods, one can modify the terminus of a nucleotide, or other heteroatom, to thereby introduce a functional linkage to the original heteroatom, an alkyl spacer and terminal heteroatom of choice which can be used to
30 couple the next synthon of the PNA oligomer or the PNA or nucleotide moiety of the PNA/DNA chimera.

- 43 -

Finally, a new linker has been described for reversibly labeling biopolymers. See U.S. Patent No. 5,410,068 which is herein incorporated by reference. Though primarily directed at DNA applications, the teachings of the above patent can be utilized to link PNA and DNA monomer subunits. This linker has an active ester and stereoselective alkyl halide reactive center.

- 5 Persons of ordinary skill will recognize that such a versatile reagent can be utilized in numerous ways to link the monomer subunits together.

In one embodiment, the hydroxyl or thiol terminus of the terminal subunit will react preferentially with the stereoselective alkyl halide center. The active ester is then preferentially reacted with an amine containing compound as described above to generate a new terminal 10 heteroatom which can be used to couple the next synthon of the PNA oligomer, PNA moiety or DNA nucleotide of the PNA/DNA chimera. Alternatively, a terminal amino group will preferentially react with the active ester. Then the stereoselective alkyl halide reactive center can be reacted preferably with an alkyl diamine, alkyl diol, or alkyl dithiol to thereby introduce a terminal heteroatom suitable for coupling the next synthon of the PNA oligomer or the PNA 15 moiety or nucleotide moiety of the PNA/DNA chimera.

Use of the above described linker also is advantageous because in addition to the above described reagents (e.g., alkyl diamine, alkyl diol, or alkyl dithiol) the compound may also be a PNA moiety or nucleotide moiety wherein Pn or Pa in a hydrogen atom. In this embodiment one is able to invert the polarity of the two subunits. This may be useful since it is known that PNA 20 can bind to DNA in both parallel and antiparallel motifs. See Egholm et al., Nature (1993) 365, 566-568.

Other linkers have been utilized in peptide synthesis. Generally these linkers are described for use in manipulating the appropriate heteroatom functional groups on biomolecules, supports and labeling reagents, but also have utility in other areas. Discussion of these linkers, as they 25 relate to peptide synthesis, can be found in the following U.S. Patents which are herein incorporated by reference. U.S. Patent Nos. 5,117,009; 5,306,562; 5,196,566; and 5,187,625. One of ordinary skill in oligonucleotide synthesis, peptide synthesis and PNA synthesis will recognize these linkers as suitable for the linking of subunits of PNAs to each other or alternatively for the linking of PNA subunits to DNA and conversely the linking of DNA subunits 30 to PNA.

Protected or unprotected, natural or unnatural nucleobases typically are those previously described or illustrated in Figure 8. Generally, the nucleobases have an exocyclic amino group

- 44 -

that is protected during the construction of the PNA-DNA chimera, then is removed after the preferred sequence is attained. On the other hand, the natural nucleobases thymine and uracil lack an exocyclic amino group, thus, usually are not protected. Protection of the exocyclic amino group of the nucleobase, if necessary, eliminates a potential reactive site during oligomer synthesis, and prevents undesired branching of the growing polymeric chain. Therefore, as in any efficient synthetic scheme, PNA-DNA chimeras can be assembled in a controlled fashion with only one likely product to result from each synthetic step.

Typically, the nucleobase protecting groups are carbamate protecting groups. Since the backbone of the PNA synthons and of the nucleotides are acid labile, an orthogonal strategy dictates that the nucleobase protecting groups necessarily be removable by different means. As described above in the synthesis of the nucleobase side chain moiety, the preferred carbamate protecting groups for the nucleobases are base labile.

Often the PNA-DNA chimera will have detectable moieties. The detectable moieties may be an intrinsic part of the chimera or may be attached to the chimera in a variety of ways, often through the use of a linker as previously described. Examples of detectable moieties include, but are not limited to, enzymes, antigens, radioactive labels, affinity labels, fluorescent labels, ultraviolet labels, infrared labels and spin labels. The detectable moiety can function, among other purposes, to monitor the synthetic assembly of the chimera or to monitor the binding of the chimera to another entity such as a DNA or RNA.


The use of labeled biomolecules is well known and is discussed in the above referenced literature related to linkers. Labeled DNA oligomers are particularly useful for DNA sequencing and other detection analyses of nucleic acids wherein the sequence specific interactions, i.e., hybridization, of DNA occurs. See U.S. Patent No. 5,149,625 which discusses labeled DNA and its utility in DNA sequencing applications and is herein incorporated by reference. Labels generally increase the sensitivity of the assay if attached to the biopolymer in a suitable manner. It is known that antisense DNA and RNA can modulate the expressions of genes because of these sequence specific interactions. Because PNA exhibits stronger sequence specific interaction with nucleic acids under certain conditions, PNA-DNA chimera are interesting candidates for further investigation as alternatives in DNA sequencing, detection assays and as therapeutic agents.

Among other methods, PNA-DNA chimeras can be constructed utilizing techniques for the synthesis of DNA sequences. DNA synthesis methods and instrumentation are well known in the industry and are widely available. Therefore, the specific design of the PNA synthons of this

- 45 -

invention will allow exploitation of commercially available DNA precursors and instrumentation for the straightforward assembly of PNA-DNA chimeras.

Generally, nucleotides commonly used in DNA synthesis and applicable for PNA-DNA chimera synthesis have the formula:



5

The entities G and B are as previously described. The entity D is a hydrogen atom, a hydroxyl group, a methoxyl group or a hydroxyl group which is protected by a protecting group. The entity Pn is a hydrogen atom or a protecting group. The group R⁶ is a protecting group that can be removed. The phosphorus linkage is typically oxidized after each coupling step to stabilize the linkage. The entity L¹ is a leaving group or a chemical bond. One example of a nucleotide moiety having the above formula, among others, is a phosphoramidite.

10 Besides nucleotides having the above structure, other nucleotide analogues that are compatible with a DNA synthesizer can be used to form PNA-DNA chimeras. For examples of DNA synthons, see U.S. Patent Nos. 4,458,066 and 4,725,677 (RE 34,069), and Smith et al.,
15 Nucleic Acids Res. (1985) 13:2399, Sproat et al., Nucleic Acids Res. (1987) 15:6181 and Sproat et al., Nucleic Acids Res. (1987) 15:4837.

20 The selection of D determine whether the nucleotide moiety is a DNA or an RNA moiety. If D is a hydrogen atom, the nucleotide is a DNA moiety. If D is a hydroxyl group or a protected derivative thereof, the nucleotide is an RNA moiety. A methoxyl group is a common substituent employed in oligomer synthesis. A number of other protecting groups including, but not limited to, silyl protecting groups, are used to protect the hydroxyl group during oligomer synthesis.


25 Whether Pn is a hydrogen atom or a protecting group is determined by the role of the nucleotide moiety in that particular synthetic step. As the oligomeric chain is assembled one moiety (or monomer) at a time, each new moiety added to the growing chain will have the atom represented by G protected, thereby rendering G unavailable as a reactive site. Therefore, if the nucleotide moiety is the next monomer to be added to the oligomer, Pn is a protecting group. (Pn will also be a protecting group if the nucleotide monomer is the first moiety to be attached to another monomer or to a solid support resin.) Conversely, if the nucleotide moiety is already part

- 46 -

of an oligomeric chain, i.e., is the moiety that will act as the nucleophilic species in the coupling reaction, Pn will be a hydrogen atom.

Suitable R⁶ substituents are described in U.S. Patent Nos. 4,458,066 and 4,725,677, which are herein incorporated by reference. The group R⁶ is typically, among other possibilities,

5 a group of the formula:



The group represented by W is an electron withdrawing group. The atoms or groups represented by each of V₁-V₃ are the same or different and are independently hydrogen, methyl and ethyl.

Preferred electron withdrawing groups include, but are not limited to, cyano, alkyl sulfonyl, aryl
 10 sulfonyl, phenyl and substituted phenyl, such as p-nitrophenyl, o-nitrophenyl and p-alkyl sulfonylphenyl.

The group represented by L¹ can be a chemical bond if, for example, the nucleotide moiety is already incorporated into a polymeric chain or attached to a solid support through a linker. The group represented by L¹ also can be a leaving group. Reaction of the preceding
 15 PNA or nucleotide moiety with the nucleotide moiety with Pn as a protecting group will displace the leaving group, thereby coupling the two moieties together. Suitable leaving groups include active esters as described in U.S. Patent Nos. 5,233,044 and 5,410,068 which are herein incorporated by reference. Other examples of leaving groups include, but are not limited to, halogens and secondary amino groups.


20 The secondary amino groups can have the formula:



The groups represented by R⁸ and R⁹ are the same or different and are independently primary, secondary or tertiary alkyl groups having 1-10 carbons atoms, or are together selected from the group consisting of cycloalkyl groups having 5-7 carbon atoms which can contain one or two
 25 nitrogen, oxygen or sulfur atoms as heteroatoms.

- 47 -

PNA moieties used in the construction of PNA-DNA chimeras have the formula:



The entities G, B, R⁷, j, g and h are as previously described. The entity Pa is a hydrogen atom or a protecting group. The entity L² is a hydroxyl group, a leaving group or a chemical bond.

- 5 Typically, as with the nucleotide moiety, the entity Pa is a hydrogen atom if the PNA moiety will act as the nucleophilic species in the coupling reaction. On the other hand, if the PNA moiety is the monomer to be coupled to a nucleophilic species, then Pa will be a protecting group, rendering G unsuitable as a reactive site.

- 10 Similarly, the identity of L² also is dependent upon the role of the PNA moiety in the synthetic sequence. If the PNA moiety is attached to an oligomer or a linker attached to a solid support, L² will be a chemical bond. However, if the PNA moiety is a monomer to be attached to a linker or a PNA or nucleotide moiety, L² will be a hydroxyl group or a leaving group. As described above for the nucleotide moiety, nucleophilic attack will displace the leaving group or activated hydroxyl group, facilitating coupling of the PNA moiety to the nucleophilic species.
- 15 Typically, the coupling step involves the generating the activated synthon, i.e., converting the hydroxyl group to a leaving group. The activation is usually carried out *in situ*. Suitable activating chemistries are well known in the art of peptide chemistry. The reagents described in USSN 0_952,025 filed on September 28, 1993 are particularly useful.

- 20 The entity L² also may preferably be an active ester such as those described in U.S. Patent Nos. 5,410,068 and 5,233,044. Preferable L² is also 1-hydroxy-7-azabenzotriazole (HOAT).

- 25 Other examples of appropriate L² groups will be readily known to those skilled in the art and preferably include, among others, imidazole, triazole, tetrazole, 3-nitro-1,2,4-triazole, thiazole, pyrrole, benzotriazole, and benzohydroxytriazole. These cycloalkyl groups also include imidazole substituted in the phenyl moiety, triazole substituted in the phenyl moiety, tetrazole substituted in the phenyl moiety, 3-nitro-1,2,4-triazole substituted in the phenyl moiety, thiazole substituted in the phenyl moiety, pyrrole substituted in the phenyl moiety, benzotriazole substituted in the phenyl moiety, and benzohydroxytriazole substituted in the phenyl moiety.

- 48 -

PNA-DNA chimeras can be assembled by a variety of methods. Probably the most efficient method will use currently available techniques and instrumentation available for DNA synthesis as previously described. In particular, nucleic acids (DNA and RNA) are now routinely synthesized using automated machines, numerous synthesis supports and various protection chemistries.

5 The following U.S. patents cover a broad range of differing supports and protection chemistries and are herein incorporated by reference. See U.S. Patent Nos. 5,262,530; 4,415,732; 4,458,066; 4,725,677 (RE 34,069); and 4,923,901. Automated equipment and reagents are commercially available from PerSeptive Biosystems, Perkin Elmer (Applied Biosystems Division) and Pharmacia. Special 5'-amino synthons are described in Smith et al.,

10 Nucleic Acids Res. (1985) 13:2399 and in Sproat et al., Nucleic Acids Res. (1987) 15:6181. Special 5'-thio synthons are described in Sproat et al., Nucleic Acids Res. (1987) 15:4837. The reagents described in the above references are suitable for use on standard DNA synthesis instruments.

The preferred commercial method for nucleic acid synthesis utilizes the above reagents

15 and methods as generally described by Koester et al. in U.S. Patent No. 4,725,677 (RE 34,069). Consequently, the preferred synthons are β -cyanoethyl phosphoramidites having acid labile protection of the backbone 5' hydroxyl group and base labile acyl-type protection of the exocyclic amino groups of the nucleobases.

The preferred acid labile backbone protecting group is 4,4'-dimethoxytriphenylmethyl (DMT). DMT is typically chosen because it can be removed fairly rapidly (1-3 minutes) during each synthetic cycle with solutions containing 1-4% dichloroacetic acid or trichloroacetic acid in dichloromethane. Protecting groups with increased acid lability compared to DMT are susceptible to premature deprotection during the acid catalyzed coupling reactions (tetrazole is typically the acidic species). Protecting groups with decreased acid lability compared to DMT require longer reaction times and/or harsher reaction conditions for complete removal. Generally, harsher acidic deprotection conditions are avoided since the purine nucleobases are particularly susceptible to decomposition in acid. Although the aforementioned problems with protecting groups and synthetic conditions may be minimal during each synthetic cycle, the cumulative effect can generate significant impurities in oligonucleotide synthesis. Accordingly, as the length of the

25 oligonucleotide increases, its purity tends to decrease.

Generally, base labile protecting groups are utilized for protection of the exocyclic amino groups of the nucleobases so that an orthogonally protected nucleic acid synthon results. The

- 49 -


- base labile protecting groups typically remain a part of the growing nucleic acid chain, then are removed simultaneously with the cleavage of synthesized nucleic acid from the solid support. A concentrated ammonium hydroxide solution is often used for the "deprotection and cleavage step." Koester et al. used base labile acyl-type protecting groups which are usually treated for 6-
- 5 24 hours at elevated temperature (about 55°C) for complete removal of these nucleobase protecting groups. Other protecting groups have been developed which are removed under the same conditions but in less time (from about 15-60 minutes). Examples of these improved protecting groups include phenoxyacetyl, t-butyl phenoxyacetyl and amidine-type protecting groups. While these protecting groups have increased base lability, typically only the time
- 10 necessary for removal is reduced.

In addition, the PNA synthons can be coupled to each other to form a PNA oligomer (PNA). Because the chemistry of the PNA synthons is compatible with commercially available synthesizers, the synthons are readily transformed into polymeric chains of various lengths and sequences.

- 15 Generally, before removal of the nucleobase protecting groups, the PNA oligomer will have the formula:



The letters K and N represent chemical bonds. The letter Q is a chemical bond or a linker as previously described. Each of L and M is the same or different and is independently a PNA moiety having the formula:



The entities G, Ba, R⁷, g, h and j are as previously described.

The oligomer can be assembled using standard peptide coupling procedures. Following completion of the desired PNA sequence, removal of all protecting groups, and cleavage from the 25 solid support, if necessary, will produce the PNA molecule. Proper choice of the support is important to avoid harsh acid treatments and preferably will allow cleavage and deprotection to occur in basic solutions. Methods for preparing suitable membrane supports are found in U.S.

- 50 -

Patent No. 4,923,901. In addition, preferably the support will be functionalized with hydroxyl groups to which the first PNA synthons is attached as an ester.

Various methods already described in the chemical literature for peptide synthesis are generally applicable to PNA oligomer synthesis. These methods include, but are not limited to,

5 solid phase peptide synthesis and solution synthesis. For example, in solid-phase synthesis, following coupling of the first amino acid, the next step is the systematic elaboration of the desired PNA chain. This elaboration involves repeated deprotection/coupling cycles. The temporary backbone protecting group on the last-coupled amino acid, such as Fmoc, is quantitatively removed by a suitable treatment, for example by base treatment with piperidine, so

10 as to liberate the N-terminal amine function.

The next desired N-protected amino acid is then coupled to the N-terminal of the last-coupled amino acid. This coupling of the C-terminal of an amino acid with the N-terminal of the last-coupled amino acid can be achieved in several ways. For example, the carboxyl group of the incoming amino acid can be reacted directly with the N-terminal of the last-coupled amino acid

15 with the assistance of a condensation reagent such as, for example, dicyclohexylcarbodiimide (DCC) (Sheehan & Hess, et al., *J. Am. Chem. Soc.*, 1955, 77, 1067) and diisopropylcarbodiimide (DIC) (Sraantakis et al., *Biochem. Biophys. Res. Commun.*, 1976, 73, 336) or derivatives thereof. Alternatively, it can be bound by providing the incoming amino acid in a form with the carboxyl group activated by any of several methods, including the initial formation of an active ester

20 derivative such as a 2,4,5-trichlorophenyl ester (Pless, et al., *Helv. Chim. Acta*, 1963, 46, 1609), a phthalimido ester (Nefkens, et al., *J. Am. Chem. Soc.*, 1961, 83, 1263), a pentachlorophenyl ester (Kupryszewski, *Roczn. Chem.*, 1961, 35, 595), a pentafluorophenyl ester (Kovacs, et al., *J. Am. Chem. Soc.*, 1963, 85, 183), an o-nitrophenyl ester (Bodanzsky, *Nature*, 1955, 175, 685), an imidazole ester (Li, et al., *J. Am. Chem. Soc.*, 1970, 92, 7608), and a 3-hydroxy-4-oxo-3,4-

25 dihydroquinazoline (Dhbt-OH) ester (Konig, et al., *Chem. Ber.*, 1973, 103, 2024 and 2034), or the initial formation of an anhydride such as a symmetrical anhydride (Wieland, et al., *Angew. Chem., Int. Ed. Engl.*, 1971, 10, 336). Benzotriazolyl N-oxytrisdimethylaminophosphonium hexafluorophosphate (BOP), "Castro's reagent" (see, e.g., Rivaille, et al., *Tetrahedron* 1980, 36, 3413) is recommended when assembling PNA molecules containing secondary amino groups.

30 Preferred reagents for activating the carboxylic acid groups include 1-hydroxy-7-azabenzotriazole (HOAT) and its phosphonium and uronium salts. See Carpino, L. J. Am. Chem. Soc., (1993) 115, 4397. Finally, activated PNA monomers analogous to the recently-reported amino acid fluorides

- 51 -

(Carpino, J. Am. Chem. Soc., 1990, 112, 9651) hold considerable promise to be used in PNA synthesis as well.

Following assembly of the desired PNA chain, including protecting groups, the next step will normally be deprotection of the amino acid moieties of the PNA chain and cleavage of the synthesized PNA from the solid support. These processes can take place substantially simultaneously, thereby providing the free PNA molecule in the desired form. Alternatively, in cases in which condensation of two separately synthesized PNA chains is to be carried out, it is possible by choosing a suitable spacer group at the start of the synthesis to cleave the desired PNA chains from their respective solid supports (both peptide chains still incorporating their side-chain protecting groups) and finally removing the side-chain protecting groups after, for example, coupling the two side-chain protected peptide chains to form a longer PNA chain.

After the PNA-DNA chimera has been synthesized and isolated, many potential uses of the various sequence combinations are realized. One such use is as a therapeutic or antisense agent. PNA-DNA chimeras can be administered to organisms in a variety of ways or forms known in the industry thereby assisting in the maintenance of a healthy organism or helping increase the rate of recovery from poor health.

PNA-DNA chimeras may be useful as primers in a polymerase reaction. The PNA-DNA chimera is contacted with a nucleic acid polymer to which the chimera recognizes and binds to, thereby beginning the polymerase reaction.

PNA-DNA chimeras also may be useful as probes for the detection of a genetic sequence.

The invention, being generally described above, is now more specifically illustrated by way of the following examples, which are not meant to limit the invention, unless otherwise noted.

Examples

Example 1

25 Synthesis of 4,4'-dimethylbenzhydrol (I)

To 4.73 mole of magnesium chips was added dropwise, at a rate necessary to maintain a vigorous reflux after initiation of the reaction, a solution containing 4.4 mole of 4-bromo toluene which had been diluted to a total of 3 liters (L) with dry tetrahydrofuran (THF). After the addition was completed, the reaction was allowed to stir until it had cooled near room temperature (about one hour). To the prepared grignard reagent was added dropwise 4.3 mole of p-tolualdehyde at a rate necessary to cause the reaction to reflux. After addition was completed,

- 52 -

the reaction was allowed to stir until it had cooled near room temperature (about 30 minutes). The reaction was then concentrated to about half volume and poured into a heterogeneous solution (briskly stirring) containing 2.5 liters of dichloromethane and a solution containing 4.8 moles of potassium hydrogen sulfate diluted to 4.5 liters with water. After addition, a solution 5 containing 3N HCl was added until all the salts had dissolved (dichloromethane layer on top). The layers were separated and the organic layer washed one time with dilute sodium phosphate buffer (pH 5). The product was dried, filtered and evaporated. Yield: 970 grams green oil. The product was recrystallized from 1.6 liters of hexane/ethylacetate (9:1). Yield: 660.1 grams (g) white solid (72%). A second crop was obtained from the mother liquor by recrystallizing from 10 500 mL ethylacetate/hexane (9:1). Yield: 108.0 g white solid (11.8%). Total Yield: 768.1 g, 3.62 mole (84%).

¹H-NMR deutero chloroform (CDCl₃): δ = 7.3-7.0 (dd, 8H), 5.7 (s, 1H), 2.3 (s, 6H), 2.2 (s, 1H)

Example 2

15 Synthesis of N-(4,4'-dimethylbenzhydroxycarbonyl)-ethylenediamine (II)

To 130 millimole (mmole) of carbonyldiimidazole (CDI) suspended in 100 mL of dichloromethane (DCM) and stirring at 0°C was added dropwise a solution of 125 mmole of 4,4'-dimethylbenzhydrol dissolved in 60 mL of dichloromethane. The reaction was allowed to stir for 30 minutes after the addition was complete. Thin layer chromatography (tlc) analysis after 30 20 minutes indicated a complete reaction. The product was transferred to a separatory funnel and washed two times with 70 mL of water. The dichloromethane layer was then dried with sodium sulfate, filtered, and evaporated. Yield: 40g white solid.

To one mole of ethylenediamine stirring at 0°C was added dropwise a solution containing the 40g of isolated product dissolved in 150 mL of dichloromethane. The reaction was then 25 allowed to stir for 30 minutes after the addition was completed. The solution was then transferred to a separatory funnel and extracted four times with 100 mL of water. (The last wash contained a small amount of brine to minimize emulsion formation.) The dichloromethane layer was then dried with sodium sulfate, filtered and evaporated. Yield: 37.8g clear yellow oil (101%)

30 ¹H-NMR (CDCl₃): δ = 7.3-7.0 (dd, 8H), 6.7 (s, 1H), 5.5 (m,1H), 3.2-3.1 (dd, 2H), 2.8-2.7 (t, 2H), 2.3 (s, 6H), 1.1 (s, 2H)

- 53 -

Example 3

Synthesis of N-(4,4'-dimethylbenzhydroxycarbonyl)-N'-trifluoroacetyl-ethylenediamine (III)

To the 37.8g of N-(4,4'-dimethylbenzhydroxycarbonyl)-ethylenediamine isolated in example 2 was added 200 mL of dichloromethane and 50 mmole of triethylamine. The solution
5 was cooled in an ice bath and then 150 mmole of ethyl trifluoroacetate was added dropwise. A white solid product crystallized over the next one hour period and was then collected by vacuum filtration. The filtrate was allowed to stir overnight and then transferred to a separatory funnel. After transfer, the solution was washed two times with sodium phosphate buffer (pH 6), dried with sodium sulfate, filtered and evaporated. The residue was recrystallized from 250 mL of
10 hexane/ethylacetate (3:2). Yield: 16.6 g white solid (34%). The product initially collected by vacuum filtration weighed 21.05g (42%) Total Yield is 37.65g (76%).

¹H-NMR (CDCl₃): δ = 7.6 (m, 1H), 7.3-7.0 (dd, 8H), 6.7 (s, 1H), 5.4 (m, 1H),
3.4-3.2 (m, 4H), 2.3 (s, 6H).

Example 4

15 Synthesis of N-[N'-4,4'-dimethylbenzhydroxycarbonyl -(2'-aminoethyl)]glycine (IV)

To 40 mmole of N-(4,4'-dimethylbenzhydroxycarbonyl)-N'-trifluoroacetyl-ethylenediamine stirring in 160 mL of dry tetrahydrofuran (THF) at 0°C was added 44 mmole of sodium hydride. The reaction was allowed to stir in an ice bath until all gas evolution had ceased and the deep blue color disappeared. To the reaction was then added 48 mmole of ethyl
20 bromoacetate. The reaction was then allowed to stir overnight while warming to room temperature. In the morning the solvent was evaporated and the residue repartitioned with 100 mL of ethylacetate and 100 mL of sodium phosphate buffer (pH 6). The organic layer was then washed one time with water and then dried with sodium sulfate, filtered and evaporated. Yield:
19.72 g orange oil (90%).

25 The residue was dissolved in 240 mL of ethanol/acetonitrile (1:1) and then 60 mL of water was added. The solution was cooled in an ice bath and then 160 mL of 2.5N aqueous lithium hydroxide was added. Reaction was allowed to stir for 1 hour (hr) and then 3 N HCl was added dropwise very slowly until the pH was 8-9 by paper. To the solution was then added 15 mL of 1M NaH₂PO₄ to adjust the pH to 7. A white precipitate then formed and the solution was then
30 concentrated on a rotovap until approximately 150 mL of solvent was removed. The residue was then extracted with 3X 100 mL of ethylacetate. All ethylacetate layers were

- 54 -

combined and back extracted one time with 1M phosphate buffer (pH 7). The ethylacetate layers were dried in sodium sulfate, filtered and evaporated. Yield: 14.3 g yellow foam.

Recrystallized from 400 mL acetonitrile. Yield: 8.35g (59%). Recrystallized again from 100 mL ACN. Yield: 7.63g (54%).

- 5 $^1\text{H-NMR}$ deutero methyl sulfoxide (d_6DMSO): $\delta = 7.7$ (m, 1H), 7.3-7.0 (dd, 8H), 6.6 (s, 1H), 3.3-3.1 (m, 4H), 2.9 (m, 2H), 2.3 (s, 6H)

Example 5

Synthesis of 2-(1'-thyminyl)acetic acid

- To 300 grams of thymine was added 750 mL hexamethyldisilazane and 15 grams of ammonium sulfate. The stirring reaction was heated at reflux until no more gas was evolved. The reaction was then cooled to 80°C and then 160 mL of ethylbromoacetate was added. Gentle heating of the reaction was continued until tlc analysis indicated that 95% of the starting material was consumed. The reaction was then cooled to 20°C in an ice bath and then 150 mL of methanol was added dropwise while stirring in the ice bath. Once the addition of methanol was complete, 2.5 liters of 3N NaOH was added carefully. The ice bath was then removed and gas was passed over the reaction rapidly to vaporize excess silanes. Then 80 grams of sodium hydroxide was added and the reaction was allowed to stir overnight. In the morning, 1 L of 6N HCl was added to the reaction to cause the product to crystallize. The product was then collected by vacuum filtration and washed with dilute aqueous hydrochloric acid. The collected product was then suspended in 1.5 L of acetonitrile and the solution allowed to reflux with stirring. After cooling overnight, the solid was again collected by vacuum filtration, washed with acetonitrile, dichloromethane, and acetonitrile. Yield: 327 grams (75%).

$^1\text{H-NMR}$ (d_6DMSO): $\delta = 12.06$ (s, 1H), 11.31 (s, 1H), 7.48 (s, 1H), 4.35 (s, 2H), 1.74 (s, 3H)

Example 6

25 Synthesis of 2,2-dimethyl-1-cyanoethoxycarbonyl-imidazole (XIV)

- To 250 mmole of carbonyldiimidazole suspended in 100 mL of dichloromethane was added 260 mmole of 2-hydroxy-2-methyl-butyronitrile. The reaction stirred for about 20 hours and then was transferred to a separatory funnel. An additional 250 mL of dichloromethane was added and the solution was then washed three times with 100 mL of water. The organic layer was then dried with sodium sulfate, filtered and then concentrated to about 50 mL. Immediately

- 55 -

thereafter, 200 mL of ether was added with brisk stirring and the solution was then cooled in an ice bath for 30 minutes. The white solid product was then collected by vacuum filtration. Yield: 29.6 grams (61%).

- 15 $^1\text{H-NMR}$ (d_6DMSO): $\delta = 8.1$ (m, 1H), 7.4 (m, 1H), 7.1 (m, 1H), 3.1 (s, 2H),
5 1.8 (s, 6H)

Example 7

Synthesis of t-Butyl 2-(1'-cytosyl)acetate (V)

To 200 mmole of cytosine was added 250 mL of DMF and 215 mmoles of potassium-t-butoxide. The reaction was then heated to 60°C with brisk stirring and then immediately cooled
10 to 0°C. To the ice cold solution was added dropwise 215 mmoles of t-butyl-bromoacetate. The reaction was allowed to stir one hour at 0°C and then it was concentrated. The residue was poured into 500 mL of water containing 30 mmoles of 3N hydrochloric acid. The solution stirred for 20 minutes and then the white solid product was collected by vacuum filtration. Yield: 32.08g (71%).

- 15 $^1\text{H-NMR}$ (d_6DMSO): $\delta = 7.5$ (d, 1H), 7.1 (s, 2H), 5.7 (d, 1H), 4.3 (s, 2H), 1.4 (s, 9H)

Example 8

Synthesis of t-Butyl 2-[N'4-2,2-dimethyl-1-cyanoethoxycarbonyl (1'-cytosyl)]acetate (VI)

To 52 mmoles of 2,2-dimethyl-1-cyanoethoxycarbonyl-imidazole in 150 mL of dichloromethane (at 0°C) was added 50 mmole of Methyl trifluoromethanesulfonate (dropwise).
20 The reaction was allowed to stir for 30 minutes and then 35 mmole of t-Butyl 2-(1'-cytosyl)acetate was added. The reaction was allowed to stir until complete by tlc analysis (24 hours). The product was transferred to a separatory funnel and extracted once with 50 mL of 5% potassium hydrogen sulfate and once with 5% sodium bicarbonate. The organic layer was then dried with sodium sulfate, filtered and evaporated. The residue was recrystallized with
25 ethylacetate. Yield: 7.35g (60%).

- 15 $^1\text{H-NMR}$ (CDCl_3): $\delta = 7.5$ (d, 1H), 7.1 (d, 1H), 4.5 (s, 2H), 2.9 (s, 2H), 1.7 (s, 6H)
1.5 (s, 9H)

Example 9Synthesis of 2-[N⁴-2,2-dimethyl-1-cyanoethoxycarbonyl(1'-cytosyl)]acetic acid (VII)

- To 25 mmole of t-Butyl 2-[N⁴-2,2-dimethyl-1-cyanoethoxycarbonyl (1'-cytosyl)]acetate was added 25 mL of dichloromethane and 50 mL of trifluoroacetic acid (TFA). The reaction as
5 allowed to stir until the ester completely hydrolyzed (four hours). The solution was then concentrated and redissolved in 10 mL of dichloromethane. The product was precipitated by adding this solution dropwise to 350 mL of briskly stirring ice cold ethyl ether. The product was then collected by vacuum filtration. Yield: 7.60g white solid (103%). [Does not appear to exist as a TFA salt.]
10 ¹H-NMR (d₆DMSO): δ = 8.0 (d, 1H), 6.9 (d, 1H), 4.5 (s, 2H), 3.2 (s, 2H), 1.5 (6H)

Example 10Synthesis of t-Butyl 2-(9'-adenyl)acetate (VII)

- To 200 mmoles of adenine was added 400 mL of dried dimethylformamide (DMF). To the stirring suspension was then added 230 mmoles of sodium hydride. The solution was allowed
15 to stir overnight at room temperature and then cooled in an ice bath for 30 minutes. Thereafter, 220 mmoles of t-butyl bromoacetate was added dropwise. The solution as then stirred for 30 minutes and then concentrated to about 50 mL under reduced pressure. The residue was then poured into 1.5 L of water containing 20 mL of 10% sodium carbonate. After stirring 30 minutes, the white solid product which precipitated was collected by vacuum filtration. The wet
20 product was then recrystallized from 300 mL of acetonitrile/water (9:1). The product crystals were collected by vacuum filtration. Yield: 25.94 grams (52%).

¹H-NMR (d₆DMSO): δ = 8.13 (s, 1H), 8.10 (s, 1H), 7.24 (s, 2H), 4.9 (s, 2H),
1.4 (s, 9H)

Example 1125 Synthesis of t-Butyl 2-[N⁶-2,2-dimethyl-1-cyanoethoxycarbonyl (9'-adenyl)]acetate (IX)

- To 2,2-dimethyl-1-cyanoethoxycarbonyl-imidazole was added 100 mL of dichloromethane. The solution was cooled in an ice bath for 30 minutes and then 50 mmole of Methyl trifluoromethanesulfonate was added dropwise. The reaction was allowed to stir 30 minutes in an ice bath and then 35 mmoles of t-Butyl 2-(9'-adenyl)acetate was added and the
30 reaction stirred until complete by tlc analysis (four days). The solution was then transferred to a

- 57 -

separatory funnel, extracted once with 70 mL of 5% potassium hydrogen sulfate, once with 5% sodium bicarbonate, and once with a dilute sodium chloride solution. The organic layer was then dried with sodium sulfate, filtered and evaporated. The white solid product was crystallized from 130 mL of ethyl acetate. Yield: 10.17 gram (77%).

- 5 ¹H-NMR (d₆DMSO): δ = 10.5 (s, 1H), 8.6 (s, 1H), 8.4 (s, 1H), 5.1 (s, 2H), 3.2 (s, 2H),
1.6 (s, 6H), 1.4 (s, 9H)

Example 12

Synthesis of 2-[N'6-2,2-dimethyl-1-cyanoethoxycarbonyl(9'-adenyl)]acetic acid (X)

To 28 mmole of t-Butyl 2-[N'6-2,2-dimethyl-1-cyanoethoxycarbonyl (9'-adenyl)]acetate
10 was added 25 mL of dichloromethane and 50 mL of trichloroacetic acid (TFA). The reaction was stirred until all the ester was hydrolyzed as indicated by tlc analysis (4 hours). The solution was then concentrated to an oil and the residue redissolved in 10 mL of dichloromethane. The product was then precipitated by dropwise addition of this solution to briskly stirring ice cold ethyl ether. The product was then collected as a white solid by vacuum filtration. Yield: 11.55 g
15 off-white solid (95%). [Product believed to exist as a TFA salt.]

¹H-NMR (d₆DMSO): δ = 8.6 (s, 1H), 8.5 (s, 1H), 5.1 (s, 2H), 3.2 (s, 2H), 1.6 (s, 6H)

Example 13

Synthesis of Benzyl 2-[6'-chloro(9'-purinyl)]acetate (XI)

To 6-chloro-2-amino purine (300 g. 1.77 mole; Pharma-Waldorf GmbH, Germany, P/N
20 471720) and potassium carbonate (366 g; 2.65 mole, Aldrich Chemical, Milwaukee, WI
(hereinafter Aldrich) P/N 34,782-5) was added dimethyl formamide (DMF, 3 L) and the solution was warmed until all the 2-amino-6-chloropurine dissolved (84° C). The mixture was then cooled in an ice bath and benzyl-2-bromoacetate (299 mL, 1.89 mole; Aldrich P/N 24,563-1) was added dropwise over the course of one and one half hours. The mixture was stirred for an additional
25 three hours at 0°C and was then stirred overnight at ambient temperature. The following day the reaction mixture was filtered and the filtrate was then poured into a solution containing 7 liters of water and 150 mL of concentrated hydrochloric acid (HCl). The mixture was stirred for 2 hr. and the product was then isolated by filtration. The product was washed thoroughly with water and subsequently recrystallized by portion-wise addition of the solid to boiling acetonitrile (3 L). The

- 58 -

very red solution was left overnight and filtered the next day. The product was washed thoroughly with methanol and then diethylether. Yield 386 g (69%)

¹H - NMR (d₆DMSO) δ = 8.14 (1 H, s), 7.4-7.3 (5 H, m), 7.02 (2 H, s), 5.21 (2 H, s), 5.08 (2H, s).

5 Example 14

Synthesis of Benzyl 2-[N'2-2-(Methylthio)ethoxycarbonyl-6'-chloro(9'-purinyl)]acetate (XII)

To 50 mmol of Benzyl 2-[6'-chloro(9'-purinyl)]acetate was added about 200 mL of freshly distilled tetrahydrofuran. The reaction was cooled for 20 minutes in an ice bath and then 20 mmol of triphosgene was added. The reaction was allowed to stir 30 minutes at 0°C and then 10 130 mmol of diisopropylethylamine was added dropwise. After stirring 20 minutes at 0°C, 70 mmol of 2-(methylthio)-ethanol was added. The reaction was allowed to stir overnight while warming to room temperature. In the morning, the reaction was concentrated to about half volume and then poured into a stirring solution containing 500 mL of water and 30 mmol of HCl. This mixture was allowed to stir for 30 minutes and then the product was then collected by 15 vacuum filtration. The product was recrystallized from ethanol. Yield 74%

¹HNMR (d₆DMSO) δ = 10.8 (1H, s), 8.5 (1H, s), 7.35 (5H, m), 5.22 (4H, m), 4.25 (2H,t), 2.75 (2H,t), 2.15 (3H,s)

Example 15

Synthesis of 2-[N'2-2-(Methylthio)ethoxycarbonyl(9'-guanyl)]acetic acid (XIII)

20 To 75 mmol of 95% sodium hydride was added about 100 mL of freshly distilled tetrahydrofuran. The solution was cooled in an ice bath for 20 minutes and then 75 mmol of 3-hydroxypropionitrile was added. Reaction was stirred at 0°C for 2 hours and then 15 mmol of Benzyl 2-[N'2-2-(Methylthio)-ethoxycarbonyl-6'-chloro(9'-purinyl)]acetate was added. The reaction was allowed to stir overnight while warming to room temperature. In the morning, the 25 solvent was completely evaporated and then a solution containing 200 mL of water, 54 grams of sodium chloride and 8 grams of K₂S₂O₇ was added. The solution was stirred briskly for 15 minutes and then the solid product filtered off. The product as purified by boiling in acetonitrile. Yield 83%.

¹HNMR (d₆DMSO) δ = 11.52 (1H, s), 11.37 (1H, s) 7.93 (1H, s), 4.9 (2H, s), 4.35 (2H,t), 2.785 (2H,t), 2.15 (3H,s)

- 59 -

Example 16

Synthesis of N-[N'-4,4'-dimethylbenzhydroxycarbonyl -(2'-aminoethyl)]-N-[2-(1'-thyminyl)acetyl]glycine (XIX)

To 3 mmole of N-[N'-4,4'-dimethylbenzhydroxycarbonyl -(2'-aminoethyl)]glycine was
5 added 15 mL of acetonitrile (ACN) and 12 mmole of N-methylmorpholine (NMM). The solution
was allowed to cool in an ice bath and then 6 mmole of triisopropylsilyl chloride was added. The
solution was allowed to stir for two hours at 0°C and then it was added to the product of the
following reaction as described below.

To 3.3 mmole of 2-(1'-thyminyl)acetic acid was added 15 mL of acetonitrile and 12
10 mmole of N-methylmorpholine. The solution was allowed to stir while cooling to 0°C and then
3.7 mmole of trimethylacetyl chloride was added to the solution. After stirring for 15 minutes
 aliquots of reaction were removed and reacted with diethylamine to determine whether complete
 anhydride formation had occurred. After tlc analysis had indicated completion formation of the
 anhydride, the above described reaction was added dropwise to the product of this reaction and
15 this mixture was then allowed to stir for 30 minutes. The product was then evaporated and the
 residue partitioned with 30 mL of ethyl ether and 30 mL of a solution containing 3% N-
 methylmorpholine in water.

The layers were separated, and the organic layer washed one time with 30 mL of a
20 solution containing 3% N-methylmorpholine in water. The organic layer was dried with sodium
 sulfate and filtered into a second flask. The total volume of the solution was adjusted to 75 mL
 by the addition of more ethyl ether. To this solution was added 12 mmole of N-methylmorpholine
 and 3 mmole of triethylamine trihydrofluoride ($\text{Et}_3\text{N} \cdot 3\text{HF}$). To the solution was added 30 mL
 of water after 5 min (pH to 7 - 8 by paper). To the solution was added additional ethyl ether and
 30 mL of a solution containing 3% N-methylmorpholine in water. The layers were separated and
25 the aqueous layer was evaporated. The residue was then partitioned with 30 mL of
 dichloromethane and 40 mL of a pH 3.5* buffer. The layers were separated and the organic layer
 was then dried with sodium sulfate, filtered and 6 mmole N-methyl morpholine was added to the
 filtrate. The filtrate was then evaporated and the residue dissolved in a minimal amount of
 dichloromethane. The product was then precipitated by dropping this solution into briskly stirring
 30 ice cold ethyl ether. The product was collected by vacuum filtration. Yield: 0.872 g (48%).

*[pH 3.5 buffer consisted of 0.2 M citric acid, 0.2M Na_2HPO_4 , 0.2M NaH_2PO_4]

- 60 -

¹H-NMR (d₆DMSO): δ = 11.3 (m, 1H), 7.7-7.4 (mm, 1H), 7.3-7.0 (m, 9H), 6.6 (m, 1H), 4.8 (s, mj, 2H), 4.4 (s, mi, 2H), 4.0 (s, mi, 2H), 3.9 (s, mj, 2H), 3.6 (t, 1/2 NMM), 3.5-3.0 (m, 4H), 2.4 (t, 1/2 NMM), 2.25 (s, 6H), 2.2 (s, 1/2 NMM), 1.7 (s, 3H) The PNA synthons prepared produced rotomers due to hindered rotation about the amide bond. When signals appear for each 5 rotomer form, they are designated mj for major signal (the larger signal) and mi for minor signal. The number of protons designated represents the total number for the combined signals. For this monomer the abundance of rotomer is approximately equal and therefore the designation is merely inserted for convenience of the reader.

Example 17

10 Synthesis of N-[N''-4,4'-dimethylbenzhydroxycarbonyl -(2''-aminoethyl)]-N-[2-[N'4-2,2-dimethyl-1-cyanoethoxycarbonyl(1'-cytosyl)]acetyl]glycine (XVI)

To 3 mmole of N-[N'-4,4'-dimethylbenzhydroxycarbonyl -(2'-aminoethyl)]glycine was added 15 mL of acetonitrile and 9 mmole of N-methylmorpholine. The solution was allowed to cool in an ice bath and then 6 mmole of triisopropylsilyl chloride was added. The solution was 15 allowed to stir for two hours at 0°C and then itwas added to the product of the following reaction as described below.

To 3.3 mmole of 2-[N'4-2,2-dimethyl-1-cyanoethoxycarbonyl(1'-cytosyl)]acetic acid was added 15 mL of acetonitrile and 9 mmole of N-methylmorpholine. The solution was allowed to stir while cooling to 0°C and then 3.7 mmole of trimethylacetyl chloride was added to the 20 solution. After stirring for 15 minutes aliquots of reaction were removed and reacted with diethylamine to determine whether complete anhydride formation had occurred. After tlc analysis had indicated complete formation of the anhydride, the above described reaction was added dropwise to the product of this reaction and this mixture was then allowed to stir for 30 minutes.

The product was then evaporated and the residue partitioned with 30 mL of ether and 30 25 mL of a solution containing 3% N-methylmorpholine in water. The layers were separated, and the organic layer washed one time with 30 mL of a solution cointaining 3% N-methylmorpholine in water. The organic layer was dried with sodium sulfate and filtered into a second flask. To this solution was added 9 mmole of N-methylmorpholine and 2.2 mmole of triethylamine trihydrofluoride. Because the pH was determined to be very high, excess triethylamine 30 trihydrofluoride was added to adjust the pH to 7 or 8 by paper. To the solution was added additional ethyl ether and 30 mL of a solution containing 3% N-methylmorpholine in water. The

- 61 -

layers were separated and the product determined to be in the aqueous layer. The organic layer was washed one time with 30 mL of 3% N-methylmorpholine in water. The water layers were combined and then evaporated to a white gel. The gel was co evaporated two times from water and one time from dry tetrahydrofuran (THF). The residue was then partitioned with 25 mL of dichloromethane and 30 mL of a pH 3.5* buffer. The product was determined to be in the dichloromethane layer. The layers were separated and the organic layer washed one time with dilute sodium chloride solution. The organic layer was then dried with sodium sulfate, filtered and evaporated. Yield: 1.61 grams yellow foam (73%). The foam was dissolved in a minimal amount of dichloromethane and the product precipitated by dropping this solution into a stirring solution of ice cold ethyl ether. Yield: 1.06 g (48%)

¹H-NMR (d₆DMSO): δ = 7.9-7.7 (m, 1H), 7.6 (m, mj, 1H), 7.4 (m, mi, 1H), 7.3-7.0 (m, 9H), 7.0-6.8 (m, 1H), 6.6 (m, 1H), 4.8 (s, mj, 2H), 4.6 (s, mi, 2H), 4.2 (s, mi, 2H), 4.0 (s, mj, 2H), 3.6 (t, 1/2 NMM), 3.5-3.0 (m, 4H), 2.4 (t, 1/2 NMM), 2.25 (s, 6H), 2.2 (s, 1/2 NMM), 1.5 (s, 6H)

*[PH 3.5 buffer consisted of 0.2 M citric acid, 0.2M Na₂HPO₄, 0.2M NaH₂PO₄]

15 Example 18

Synthesis of N-[N''-4,4'-dimethylbenzhydrol oxycarbonyl -(2''-aminoethyl)]-N-[2-[N'6-2,2-dimethyl-1-cyanoethoxy carbonyl(9'-adenyl)]acetyl]glycine (XVII)

To 6 mmole of N-[N'-4,4'-dimethylbenzhydrol oxycarbonyl -(2'-aminoethyl)]glycine was added 35 mL of acetonitrile and 24 mmole of N-methylmorpholine. The solution was allowed to cool in an ice bath and then 6 mmole of triisopropylsilyl chloride was added. An additional 3 mmole of triisopropylsilyl chloride was added because the tlc analysis of the ester formation indicated incomplete reaction. The solution was allowed to stir for a total of 1.5 hours at 0°C and then was added to the product of the following reaction as described below.

To 7 mmole of 2-[N'6-2,2-dimethyl-1-cyanoethoxy carbonyl(9'-adenyl)]acetic acid was added 30 mL of acetonitrile and 28 mmole of N-methylmorpholine. The solution was allowed to stir while cooling to 0°C and then 7.7 mmole of trimethylacetyl chloride was added to the solution. After stirring for 20 minutes aliquots of reaction were removed and reacted with diethylamine to determine whether complete anhydride formation had occurred. Because the anhydride did not appear to completely form, an additional 0.7 mmole of trimethylacetyl chloride was added and the reaction was stirred for an additional 10 min. After tlc analysis had indicated

- 62 -

completion formation of the anhydride, the above described reaction was added dropwise to the anhydride product of this reaction and this mixture was then allowed to stir for 30 minutes.

The product was then evaporated and the residue partitioned with 60 mL of ethyl ether and 60 mL of a solution containing 3% N-methylmorpholine in water. The layers were separated,
5 and the organic layer washed one time with 30 mL of a solution containing 3% N-methylmorpholine in water. The organic layer was dried with sodium sulfate and filtered into a second flask. To this solution was added 24 mmole of N-methylmorpholine and 6 mmole of triethylamine trihydrofluoride. To the solution was added 60 mL of water and then the solutions were stirred until everything dissolved (pH at about 8 by paper). The layers were separated and
10 the aqueous layer was evaporated. The residue was then partitioned with 60 mL of dichloromethane and 80 mL of a pH 3.5* buffer. The layers were separated and the organic layer was then dried with sodium sulfate, filtered and 12 mmole N-methyl morpholine was added to the filtrate. The filtrate was then evaporated and the residue dissolved in a minimal amount of dichloromethane. The product was then precipitated by dropping this solution into briskly stirring
15 ice cold ethyl ether. The product was collected by vacuum filtration. Yield: 2.58 g (57%).

¹H-NMR (d₆DMSO): δ = 10.5 (s, 1H), 8.5 (d, 1H), 8.3 (d, 1H), 7.7 (m, mj, 1H), 7.4 (m, mi, 1H), 7.3-7.0 (m, 8H), 6.6 (m, 1H), 5.2 (s, mj, 2H), 5.1 (s, mi, 2H), 4.2 (s, mi, 2H), 4.0 (s, mj, 2H), 3.6 (t, 1/2 NMM), 3.5-3.0 (m, 4H), 2.4 (t, 1/2 NMM), 2.25 (s, 6H), 2.2 (s, 1/2 NMM), 1.6 (s, 6H)

20 Example 19

Synthesis of N-[N''-4,4'-dimethylbenzhydroxycarbonyl-(2'-aminoethyl)]-N-[2-[N'2-2-(Methylthio)ethoxycarbonyl(9'-guanyl)acetyl]glycine (XVIII)

To 5 mmole of N-[N'-4,4'-dimethylbenzhydroxycarbonyl-(2'-aminoethyl)]glycine was added 25 mL of acetonitrile and 20 mmole of N-methylmorpholine. The solution was allowed to cool in an ice bath and then 10 mmole of triisopropylsilyl chloride was added. The solution was allowed to stir for 1.5 hours at 0°C and then was added to the product of the following reaction as described below.

To 6 mmole of 2-[N'2-2-(Methylthio)ethoxycarbonyl(9'-guanyl)]acetic acid which was co-evaporated 2 x from 10 mL of dry DMF was added 25 mL of acetonitrile. The solution was allowed to stir while cooling to 0°C over 20 minutes. Thereafter, 7 mmole of trimethylacetyl chloride was added. Next, 20 mmole of N-methylmorpholine was added dropwise and the

- 63 -

solution was allowed to stir for 20 minutes. (As usual, aliquots of reaction were removed and reacted with diethylamine to determine whether complete anhydride formation had occurred.)

- After tlc analysis had indicated complete formation of the anhydride, the above described reaction was added dropwise to the product of this reaction and this mixture was then allowed to
5 stir for 1 hr. The product was then evaporated (not to dryness) and the residue partitioned with 50 mL of ethyl ether and 50 mL of a solution containing 3% N-methylmorpholine in water. The layers were separated, and the organic layer was increased in volume by 20 mL (ether added) and then it was washed one time with 30 mL of a solution containing 3% N-methylmorpholine in water. The organic layer was dried with sodium sulfate and filtered into a second flask. To this
10 solution was added 20 mmole of N-methylmorpholine and 5 mmole of triethylamine trihydrofluoride. To the solution was added 50 mL of a solution containing 3% N-methylmorpholine in water (pH at about 8 by paper). The layers were separated and the aqueous layer was concentrated to 5-10 mL. This was transferred to a separatory funnel and 50 mL of ethyl acetate and 75 mL of pH 3.5* buffer was added. The layers were separated and the
15 organic layer was then dried with sodium sulfate, filtered and 10 mmole N-methyl morpholine was added to the filtrate. The filtrate was then evaporated and the residue dissolved in a minimal amount of dichloromethane. The product was then precipitated by dropping this solution into 200 mL ice cold ethyl ether. The product was collected by vacuum filtration. Yield: 1.65 g (43%).
20 $^1\text{H-NMR}$ ($d_6\text{DMSO}$): $\delta = 11.4$ (s, 1H), 7.8 (d, 1H), 7.6 (m, mj, 1H), 7.5 (m, mi, 1H), 7.3-6.9 (m, 9H), 6.6 (m, 1H), 5.0 (s, mj, 2H), 4.9 (s, mi, 2H), 4.4-4.2 (m, 2H), 4.16 (s, mi, 2H), 4.0 (s, mj, 2H), 3.6 (t, 1/2 NMM), 3.55-3.0 (m, 4H), 2.8-2.6 (m, 2H), 2.4 (t, 1/2 NMM), 2.25 (m, 6H), 2.2 (s, 1/2 NMM), 2.1 (s, 3H)

Example 20

- 25 Synthesis of N-[N''-4,4'-dimethylbenzhydroxycarbonyl -(2''-aminoethyl)]-N-[2-[N'2-2-(Methylsulfonyl)ethoxycarbonyl(9'-guanyl)]acetyl]glycine

To 1 mmole of N-[N''-4,4'-dimethylbenzhydroxycarbonyl -(2''-aminoethyl)]-N-[2-[N'²-2-(Methylthio)ethoxycarbonyl(9'-guanyl)]acetyl]glycine was added 6 mL of water and 1 mmole of N-methylmorpholine. The solution was stirred until all the solid dissolved. Once
30 dissolved, 1 mmole sodium tungstate was added to the stirring solution. Then 2.5 mmole of hydrogen peroxide (3% hydrogen peroxide in water) was added. The reaction as allowed to stir

- 64 -

and was monitored by HPLC analysis. After an hour of stirring, the reaction was heated to 50°C to increase the rate of oxidation. Because oxidation did not appreciably increase, the reaction was then cooled and an additional 2 mL of 3% hydrogen peroxide in water was added. Thereafter, 250 microliters (μ L) of 3% hydrogen peroxide solution was added every five minutes until HPLC analysis indicated that only about 5% unoxidized material remained. The reaction was allowed to stir for an additional 30 minutes and then transferred to a separatory funnel. To the reaction was added 15 mL of dichloromethane and 15 mL of pH 3.5* buffer. Because an emulsion formed, to the solution was added 10 mL of brine and the solution was allowed to stand until separated. The organic layer was collected, dried with sodium sulfate, filtered and 100 μ L of N-methylmorpholine was added to the filtered solution. Because the addition of N-methylmorpholine gave a heterogeneous solution, the entire solution was returned to the separatory funnel and 10 mL of water, 10 mL of brine, and 10 mL dichloromethane was added. The layers were separated and the organic layer was collected, dried with sodium sulfate, filtered and 200 mL of N-methylmorpholine added to the filtered product. The solution was evaporated and the residue dissolved in a minimum amount of dichloromethane. The product was then precipitated by dropwise addition of this solution to briskly stirring ice cold ethyl ether. The white solid product was collected by vacuum filtration. Yield: 0.561 g yellow solid (75%).
 1 H-NMR (d₆DMSO): δ = 11.4 (s, 1H), 7.8 (d, 1H), 7.7- 7.5 (m, 1H), 7.3-6.9 (m, 9H), 6.6 (m, 1H), 5.0 (s, m, 2H), 4.9 (s, mj, 2H), 4.6-4.4 (m, 2H), 4.0 (s, m, 2H), 3.9 (s, mj, 2H), 3.6 (t, 1/2 NMM), 3.55-3.2 (m, 6H), 3.2 (s, 3H), 2.4 (t, 1/2 NMM), 2.25 (m, 6H), 2.2 (s, 1/2 NMM)

Example 21

Synthesis of PNA sequence: H₂N-CTTCTCC-CONH₂

Synthesis resin: 50 Milligrams of Boc-BHA-PEG-PS from PerSeptive Biosystems (P/N GEN063050) with amino group loading of 0.145 mmole/gram.

25 Scale: 7.25 micromole (μ M) scale synthesis

Other equivalents:

5 equivalents synthon 36 μ M

4 equivalents HATU¹ 11 milligrams (mg) per coupling

10 equivalents N-methylmorpholine 8 μ L per coupling

30 ¹HATU = O-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate

- 65 -

- Monomer was prepared immediately before each coupling step. To the dry powder in a 1 mL centrifuge tube was added 180 μ L of a solution containing 0.4 M N-methylmorpholine in dimethylformamide (DMF)/dichloromethane (DCM) (1:1) to dissolve. To the solution was then added 180 μ L of 0.16M HATU dissolved in DMF. The solution was then mixed and used immediately for coupling reactions. (Final monomer concentration was approximately 0.1 M)
- 5 immediately for coupling reactions. (Final monomer concentration was approximately 0.1 M)

Synthetic Cycle

Step No.	Description	Reagents	Reaction Time (min)
1	Deblock Terminal Amino Protecting Group	Trifluoroacetic Acid (TFA)/m-cresol (95:5)	2.5
2	Repeat step 1: 1 time		
3	Wash	DMF/DCM (1:1)	
4	Neutralize	Pyridine	
5	Couple	Activated Synthon Coupling Mixture prepared as described above	15
6	Wash	DMF/DCM (1:1)	
7	Perform Kaiser Test on sample of resin		4
8	Capping	5% acetic anhydride/DMF	2.5
9	Wash	DMF/DCM (1:1)	
10	Repeat steps 1-9 until polymer is assembled		

Cleavage:

- Removed 7.2 milligram (mg) of resin. To the resin, in an Ultrafree device (Millipore P/N SE3P230J3), was added 100 μ L of tetrahydrofuran and 300 μ L of concentrated ammonium hydroxide solution. The tube was sealed and the solution heated at 55°C overnight. The solution was removed from the beads by carefully pipetting the beads to an Ultrafree device (Millipore P/N SE3P230J3) followed by centrifugation. The resin beads were then washed four times by the addition of dried THF followed by centrifugation. Finally the resin was dried in vacuum.

- 66 -

- The resin was again transferred to a Ultrafree device (Millipore P/N SE3P230J3) and then subjected to High Cleavage Acid[#] for 1.5 hours. The acid cleavage solution was then removed by centrifugation and the resin washed two times with more High Cleavage Acid solution. To the collected acid solution was then added 1 mL of ether and the centrifuge tube was centrifuged until the PNA oligomer precipitated. The ether was decanted and the PNA pellet was washed two more times with ether by suspension of the pellet followed by centrifugation to regenerate a pellet. The residual ether was allowed to completely evaporate from the pellet and then the pellet was dissolved in 1 mL of a solution of 0.1% TFA in water. Reversed phase HPLC analysis of the crude product obtained is represented in Figure 9. Further, the product was analyzed by Matrix Assisted Laser Desorption Ionization-time of flight (MALDI-TOF) Mass Spectrometry on a prototype mass spectrometer. Calculated molecular weight was (M+H) 1822 amu, mass found was 1823 amu (within the error of the mass spec apparatus).
- 5
10

[#]High Cleavage Acid = TFA/trifluoromethanesulfonic acid (TFMSA)/m-cresol (7:2:1)

Example 22

- 15 Synthesis of H₂N-CGCTATACCC-CONH₂

Synthesis resin: 80 Milligrams of Boc-BHA-PEG-PS from PerSeptive Biosystems (P/N GEN063050) with amino group loading of 0.145 mmole/gram.

Scale: 11.6 micromole (μ M) scale synthesis

Other equivalents:

- 20 5 equivalents synthon 58 μ M
4 equivalents HATU 18 mg per coupling
10 equivalents N-methylmorpholine 8 μ L per coupling

Monomer was prepared immediately before each coupling step. To the dry powder in a 1 mL centrifuge tube was added 145 μ L of a solution containing 0.8 M N-methylmorpholine in DMF/DCM (2:1) to dissolve. To the solution was then added 145 μ L of 0.32 M HATU dissolved in DMF. The solution was then mixed and used immediately for coupling reactions. (Final monomer concentration was about 0.2 M)

25

- 67 -

Synthetic Cycle

Step No.	Description	Reagents	Reaction Time (min)
1	Deblock Terminal Amino Protecting Group	Trifluoroacetic Acid (TFA)/m-cresol (95:5)	1
2	Repeat step 1: 1 time		
3	Wash	DMF/DCM (1:1)	
4	Neutralize	Pyridine	
5	Couple	Activated Synthon Coupling Mixture prepared as described above	10
6	Wash	DMF/DCM (1:1)	
7	Perform Kaiser Test on sample of resin		4
8	Capping	5% acetic anhydride/DMF	2
9	Wash	DMF/DCM (1:1)	
10	Repeat steps 1-9 until polymer is assembled		

Notes: Kaiser test was slightly positive at coupling #8 (cytosine synthon). Kaiser was very positive at coupling #9 (guanine synthon). Had to double couple at step 9. Let coupling reaction at coupling #10 (cytosine synthon) go 15 minutes. Kaiser still positive. Performed double coupling at coupling #10. After final wash, the resin was dried in vacuum. Total weight: 0.1087 g (weight increase 28.7 mg)

Cleavage:

Removed 7.2-7.5 milligram (mg) of resin. To the resin, in Ultrafree device (Millipore P/N SE3P230J3), was added 100 μ L of tetrahydrofuran and 300 μ L of concentrated ammonium hydroxide solution. The tube was sealed and the solution heated at 56°C for 2 hours. The solution was removed from the beads by carefully pipetting the beads to a Ultrafree device (Millipore P/N SE3P230J3) followed by centrifugation. The resin beads were then washed four times by the addition of dry THF followed by centrifugation. Finally, the resin was dried in vacuum.

- 68 -

- The resin was again transferred to a Ultrafree device (Millipore P/N SE3P230J3) and then subjected to High Cleavage Acid[#] for 1 hour. The acid cleavage solution was then removed by centrifugation and the resin was again treated with High Cleavage Acid for 1 hour. The acid cleavage solution was then removed by centrifugation whereby both acid cleavage solutions were
- 5 combined in the bottom of the centrifuge tube of the Ultrafree device. To the collected acid solution was then added 1 mL of ether and the centrifuge tube was centrifuged until the PNA oligomer precipitated. The ether was decanted and the PNA pellet was washed two more times with ether by suspension of the pellet followed by centrifugation to regenerate a pellet. The residual ether was allowed to completely evaporate from the pellet and then the pellet was
- 10 dissolved in 1 mL of a solution of 0.1% TFA in water. Reversed phase analysis of the crude oligomer is represented in Figure 10. Further, the product was analyzed by Matrix Assisted Laser Desorption Ionization-time of flight (MALDI-TOF) Mass Spectrometry on a prototype mass spectrometer. Calculated molecular weight was 2648.5 amu, mass found was (M+H) 2650 amu (within the error of the mass spectrometric apparatus).
- 15 #High Cleavage Acid = TFA/trifluoromethanesulfonic acid (TFMSA)/m-cresol (7:2:1)

Example 23

Synthesis of PNA/DNA Chimera:

- Chimera sequence synthesized: DMBoc-HN-CACAC-CONH-linker-5'-CCAGT-3'-OH,
wherein the underlined sequence represents the PNA sequence and the **bold** sequence represents
20 the DNA sequence.

Procedure:

- A support bound 5'-amine modified DNA oligomer having the sequence MMT-
aminohexyl-CCAGT was synthesized using a commercially available EXPEDITE® DNA
synthesizer (PerSeptive Biosystems) running a standard protocol for a 0.2 μM scale synthesis.
- 25 The synthesis support was an 0.2 μM MEMSYN® synthesis device (P/N GEN050034) and the
synthons were standard phosphoramidites having acyl (benzoyl, isobutyryl) exocyclic amino
protecting groups. The final coupling was performed using a commercially available MMT-
aminohexyl-phosphoramidite as described by the manufacturer (PerSeptive Biosystems P/N
GEN080020). The momomethoxytrityl (MMT) group was removed by performing two standard
30 deblocking cycles on the DNA synthesizer.

The MEMSYN® device was then transferred to a prototype PNA synthesizer. The remaining PNA coupling cycles were performed on the Prototype synthesizer running a cycle optimized for delivery of reagents to the column. Generally the coupling cycle was as follows:

Step No.	Description	Reagent(s)	Reaction Time (min)
1	Wash	DMF/DCM (1:1)	
2	Purge column with Gas		0.167
3	Wait		0.167
4	Deblock Terminal Amino Protecting Group	25% DCA ^{&} in DCM	2
5	Repeat Step 4: 1 time		
6	Purge column with Gas		0.167
7	Wash	DMF/DCM (1:1)	
8	Purge column with Gas		0.167
9	Neutralize	10% Pyridine in DMF	
10	Wash	DMF/DCM (1:1)	
11	Deliver Monomer	Activated Synthon Coupling Mixture [®]	
12	Couple	Activated Synthon Coupling Mixture (Stop Flow)	8
13	Repeat Steps 11-12: 1 time		
14	Wash	DMF/DCM (1:1)	
15	Repeat Steps 1-14 until the polymer is assembled		

[&]Dichloroacetic Acid (DCA)

- 5 [®] Activated Synthon Coupling Mixture comprised PNA synthon, HATU, and N-methylmorpholine in a molar ratio of approximately (0.1M : 0.08M : 0.2M)

The final DMBhoc group was not removed after synthesis. IT is essential that the terminal amino group remain protected until after the ammonium hydroxide deprotection of the side chain protecting groups. Premature removal will result in partial degradation of the PNA portion of the

- 70 -

oligomer as described in USSN 09/109,548 entitled " " which was filed on , 199
and is herein incorporated by reference.

Cleavage:

5 The MEMSYN® device was disassembled and the two membrane synthesis supports were removed. One of the membranes was cut into quarters. To one quarter was added 2-3 drops of TFA. The strong yellow color indicated the presence of the cation of DMBhoc. This membrane piece was then washed with DCM and treated with ninhydrin. The purple color indicated the presence of terminal amino groups as expected.

10 The remaining synthesis membrane was added to a sealable centrifuge tube. To the tube was added 1 mL of concentrated ammonium hydroxide. The tube was tightly sealed and heated to 55°C for 6 hr. The ammonium hydroxide solution was removed and concentrated to dryness on a speed vac evaporator. The residue was redissolved in 200 µL of 50 millimolar ammonium acetate buffer pH 7.


15 Reverse phase HPLC analysis of the crude oligomer is represented in Figure 11. The major product observed was purified by collecting the peak as it eluted from the HPLC detector. Purity of the isolated fraction was confirmed by reanalysis of the isolated product by HPLC. The chromatogram of the product is depicted in Figure 12. The impurity peaks observed in the reanalysis chromatogram were confirmed to be buffer impurities by running the gradient without injection of sample (see Figure 13). Further, the isolated product was analyzed by Matrix 20 Assisted Laser Desorption Ionization-time of flight (MALDI-TOF) Mass Spectrometry on a prototype mass spectrometer. Calculated molecular weight was 3184.7 amu, mass found was (M-H) 3183.7 amu (within the error of the mass spectrometric apparatus).

- 71 -

CLAIMS

What is claimed is:

1. A synthetic, substantially pure composition of matter comprising:
KLQMN
wherein
- 4 K and N are chemical bonds;
- 5 Q is a linker or chemical bond;
- 6 one of L and M is a nucleotide moiety of the formula:




7 wherein

9 G is a secondary nitrogen atom, a tertiary nitrogen atom having an alkyl
10 substituent, an oxygen atom or a sulfur atom;

11 B is a protected or unprotected, natural or unnatural nucleobase;
12 and D is a hydrogen atom, a hydroxyl group, a methoxyl group or a hydroxyl group which
13 is protected by a protecting group;

14 the other of L and M is a PNA moiety of the formula:



15
16 wherein

17 G is a secondary nitrogen atom, a tertiary nitrogen atom having an alkyl
18 substituent, an oxygen atom or a sulfur atom;

19 B is a protected or unprotected, natural or unnatural nucleobase;

20 R7 is selected from the group consisting of hydrogen and a side chain of a
21 protected or unprotected naturally occurring α amino acid; and

- 72 -

22 each of j, g and h is the same or different and is independently zero or or an integer
 23 from one to five.


1 2. The compound of claim 1 wherein B is selected from the group consisting of adenine,
 2 cytosine, guanine, thymine, uracil, pseudo isocytosine, 5-methyl cytosine, hypoxanthine,
 3 isocytosine, pseudouracil and 2,6-diaminopurine.

1 3. The compound of claim 1 wherein at least one of K or N is a covalent bond.

1 4. The compound of claim 1 wherein B is a protected natural or unnatural nucleobase
 2 comprising an exocyclic amino group protected by a base labile protecting group.

1 5. The compound of claim 4 wherein the base labile protecting group is a carbamate
 2 protecting group.

1 6. The compound of claim 5 wherein the carbamate protecting group is an ethoxycarbonyl
 2 group having the formula:



3 4 wherein

5 5 W is an electron withdrawing group; and

6 6 the atom or group represented by each of R²-R⁴ is the same or different and is
 7 7 independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl,
 8 8 n-butyl and t-butyl.

1 7. The compound of claim 3 wherein K is a covalent bond which attaches L to at least one
 2 other nucleotide moiety having a backbone protecting group or PNA moiety having a backbone
 3 protecting group.


1 8. The compound of claim 7 wherein the backbone protecting group is an acid labile
 2 protecting group.

1 9. The compound of claim 1 comprising a detectable moiety.

- 73 -

1 10. The compound of claim 9 wherein the detectable moiety is selected from the group
 2 consisting of enzymes, antigens, radioactive labels, affinity labels, fluorescent labels, ultraviolet
 3 labels and infrared labels.

1 11. A PNA synthon having the formula:



2 3 wherein

4 Pg is an acid labile protecting group;

5 G is a secondary nitrogen atom, a tertiary nitrogen atom having an alkyl substituent, an
 6 oxygen atom or a sulfur atom;

7 Ba is a natural or unnatural nucleobase having an exocyclic amino group protected by a
 8 base labile amino protecting group;

9 R⁷ is selected from the group consisting of hydrogen and a side chain of a protected or
 10 unprotected naturally occurring α amino acid; and

11 each of j, g and h is the same or different and is independently zero or an integer from
 12 one to five.

1 12. The compound of claim 11 wherein G is a secondary nitrogen atom.


1 13. The compound of claim 12 wherein Pg is a carbamate protecting group.

1 14. The compound of claim 11 wherein Ba is selected from the group consisting of adenine,
 2 cytosine, guanine, pseudo isocytosine, 5-methyl cytosine, isocytosine and 2,6-diaminopurine.

1 15. The compound of claim 11 wherein the base labile amino protecting group is a carbamate
 2 protecting group.

- 74 -

- 1 16. A PNA synthon having the formula:



3 wherein

4 Pg is an acid labile amino protecting group; and

5 Ba is a natural or unnatural nucleobase having an exocyclic amino group protected by a
6 base labile amino protecting group.


1 17. The compound of claim 16 wherein Pg is a carbamate protecting group.

1 18. The compound of claim 17 wherein the carbamate protecting group is
2 4,4'-dimethylbenzhydroxycarbonyl.

1 19. The compound of claim 16 wherein the Ba is selected from the group consisting of
2 adenine, cytosine, guanine, pseudo isocytosine, 5-methyl cytosine, isocytosine and 2,6-
3 diaminopurine.

1 20. The compound of claim 16 wherein the base labile amino protecting group is a carbamate
2 protecting group.

1 21. The compound of claim 20 wherein the carbamate protecting group is an ethoxycarbonyl
2 group having the formula:



4 wherein


5 W is an electron withdrawing group; and

6 the atom or group represented by each of R²-R⁴ is the same or different and is
7 independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl,
8 n-butyl and t-butyl.

- 75 -

1 22. The compound of claim 20 wherein the carbamate protecting group is
 2 9-fluorenylmethyloxycarbonyl.


1 23. The compound of claim 20 wherein the carbamate protecting group is a 1-
 2 cyanoethoxycarbonyl group having the formula:



3
 4 wherein

5 the atom or group represented by each of R^2-R^4 is the same or different and is
 6 independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl,
 7 n-butyl and t-butyl.

1 24. The compound of claim 20 wherein the carbamate protecting group is a sulfo-
 2 ethoxycarbonyl group having the formula:




3
 4 wherein
 5 n is one or two;

6 the atom or group represented by each of R^2-R^4 is the same or different and is
 7 independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl,
 8 n-butyl and t-butyl; and

9 R^5 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, t-
 10 butyl and a substituted or unsubstituted phenyl group.

1 25. The compound of claim 24 wherein the phenyl group has the formula:




2
 3 wherein

- 76 -


4 the atom or group represented by each of a-e is the same or different and is independently
 5 selected from the group consisting of F, Cl, Br, I, hydrogen, methyl, ethyl, isopropyl, n-propyl, n-
 6 butyl, t-butyl, phenyl, methoxy, ethoxy, -NO₂, -CN, -SO₃H, -SCH₃ and -(O)SCH₃.

1 26. A PNA synthon having the formula:



2
 3 wherein

4 Pg is an acid labile amino protecting group of the formula:




5
 6 wherein

7 each of A₁-A₁₀ is the same or different and is independently selected from the
 8 group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, hydroxy,
 9 methoxy, ethoxy, amide and ester groups; and

10 R⁴ is selected from the group consisting of hydrogen, methyl and ethyl; and

11 Ba is a natural or unnatural nucleobase having an exocyclic amino group protected by a
 12 base labile amino protecting group wherein the base labile protecting group has the formula:



13
 14 wherein

15 W is an electron withdrawing group; and

16 the atom or group represented by each of R²-R⁴ is the same or different and is
 17 independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl,
 18 n-butyl and t-butyl.


- 77 -

1 27. The compound of claim 26 wherein the base labile protecting group is 2,2-dimethyl-1-
2 cyanoethoxycarbonyl.

1 28. The compound of claim 26 wherein the base labile protecting group is 2-(methylsulfonyl)ethoxycarbonyl or 2-(phenylsulfonyl)ethoxycarbonyl.


1 29. A PNA synthon of claim 16 having the formula:

2




1 30. A PNA synthon of claim 16 having the formula:

2



- 78 -


- 1 31. A PNA synthon of claim 16 having the formula:



2

- 3 wherein n is one or two.

- 1 32. A PNA synthon of claim 16 having the formula:




2

- 3 wherein n is one or two.

- 79 -


1 33. A PNA synthon having the formula:

2



1 34. A PNA synthon of claim 16 having the formula:

2



1 35. A synthetic, substantially pure composition of matter comprising:

2 KLQMN


3 wherein

4 K and N are chemical bonds;

5 Q is a linker or chemical bond; and

- 80 -

6 each of L and M is the same or different and is independently a PNA moiety having the
7 formula:



9 wherein

10 G is a secondary nitrogen atom, a tertiary nitrogen atom having an alkyl
11 substituent, an oxygen atom or a sulfur atom;

12 Ba is a natural or unnatural nucleobase having an exocyclic amino group protected
13 by a base labile amino protecting group;

14 R⁷ is selected from the group consisting of hydrogen and a side chain of a
15 protected or unprotected naturally occurring α amino acid;

16 each of j, g and h is the same or different and is independently zero or an integer
17 from one to five.


1 36. A method of synthesizing a molecule comprising the steps of:

2 (a) providing a pair of compounds Y and Z,

3 wherein

4 one of Y and Z is a nucleotide moiety comprising a trivalent phosphorus having the

5 formula:



7 wherein


8 Pn is a hydrogen atom or a protecting group;

9 G is a secondary nitrogen atom, a tertiary nitrogen atom having an alkyl
10 substituent, an oxygen atom or a sulfur atom;

11 B is a protected or unprotected, natural or unnatural nucleobase;


- 81 -

- 12 D is a hydrogen atom, a hydroxyl group, a methoxyl group or a hydroxyl group
 13 which is protected by a protecting group;
 14 R⁶ is a protective group which can be eliminated; and
 15 L¹ is a leaving group or chemical bond;
 16 the other of Y and Z is a PNA moiety the formula:



- 17
 18 wherein
 19 Pa is a hydrogen atom or a protecting group;
 20 G is a secondary nitrogen atom, a tertiary nitrogen atom having an alkyl
 21 substituent, an oxygen atom or a sulfur atom;
 22 B is a protected or unprotected, natural or unnatural nucleobase;
 23 R⁷ is selected from the group consisting of hydrogen and a side chain of a
 24 protected or unprotected naturally occurring α amino acid;
 25 L² is a hydroxyl group, a leaving group or a chemical bond; and
 26 each of j, g and h is the same or different and is independently zero or or an integer
 27 from one to five.;
 28 one of Pn and Pa is a hydrogen atom;
 29 (b) coupling Y to Z; and
 30 (c) oxidizing the trivalent phosphorus.

- 1 37. The method of claim 36 wherein R⁶ is a group of the formula:



- 2
 3 wherein
 4 the atoms or groups represented by each of V₁-V₃ is the same or different and is
 5 independently selected from the group consisting of hydrogen, methyl and ethyl; and
 6 W is an electron withdrawing group.

- 82 -

- 1 38. The method of claim 36 wherein L¹ is selected from the group consisting of F, Cl, Br, I,
2 and a secondary amino group of the formula:

3 -NR⁸R⁹

4 wherein

5 the groups represented by each of R⁸ and R⁹ is the same or different and is
6 independently selected from the group consisting of primary, secondary or tertiary alkyl groups
7 having 1-10 carbons atoms, or are together selected from the group consisting of cycloalkyl
8 groups having 5-7 carbon atoms which can contain one or two nitrogen, oxygen or sulfur atoms
9 as heteroatoms.

- 1 39. The method of claim 36 wherein at least one B is a protected natural or unnatural
2 nucleobase, Ba, comprising a base labile protecting group.

- 1 40. The method of claim 39 comprising the additional steps of:

- 2 (c) removing whichever of Pn and Pa is not the hydrogen atom; and
3 (d) removing the base labile protecting group.

- 1 41. The method of claim 36 wherein said molecule is attached to a solid support.

- 1 42. The method of claim 41 comprising the additional steps of:

- 2 (c) removing whichever of Pn and Pa is not the hydrogen atom creating a coupling
3 site; and

- 4 (d) coupling at least one other nucleotide or PNA moiety having a backbone
5 protecting group to said coupling site.

- 1 43. The method of claim 42 further comprising the additional steps of:

- 2 (e) removing the backbone protecting group creating another coupling site; and
3 (f) coupling at least one other nucleotide or PNA moiety having a backbone
4 protecting group to said other coupling site.

- 1 44. The method of claim 43 wherein the steps (e) and (f) are performed a plurality of times.

- 1 45. The method of claims 42, 43 or 44 wherein at least one B is a protected natural or
2 unnatural nucleobase comprising a base labile protecting group.

- 83 -

1 46. The method of claim 45 further comprising the additional steps of:

2 (g) removing the base labile protecting group; and


3 (h) cleaving said molecule from the solid support.

1 47. The method of claim 46 further comprising the additional step of:

2 (i) removing the backbone protecting group.

1 48. The method of claim 39 wherein the PNA moiety has a backbone protecting group and the

2 moiety has the formula:



3 wherein

5 Pg is an acid labile protecting group; and

6 Ba is a natural or unnatural nucleobase having an exocyclic amino group protected by a

7 base labile amino protecting group.

1 49. The method of claim 39 wherein Ba is selected from the group consisting of adenine,

2 cytosine, guanine, pseudo isocytosine, 5-methyl cytosine, isocytosine and 2,6-diaminopurine.

1 50. A method for synthesizing an acid labile amino protected backbone comprising the steps
2 of:

3 (a) providing an alcohol;


4 (b) coupling the alcohol using a carbonyl equivalent to a diamine forming a carbamate
5 protecting group on one amino group;

6 (c) forming an acetamide derivative with an amino group of said diamine not
7 protected as a carbamate;

8 (d) converting the acetamide derivative to a alkyl carboxy group.

- 84 -

- 1 51. The method of claim 50 wherein the alcohol is a benzhydrol derivative having the formula:



2


3 wherein

4 each of A₁-A₁₀ is the same or different and is independently selected from the group
 5 consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, hydroxy, methoxy,
 6 ethoxy, amide and ester groups; and

7 R⁴ is selected from the group consisting of hydrogen, methyl and ethyl.

- 1 52. The method of claim 50 wherein the diamine is ethylene diamine or methylene diamine.


- 1 53. An acid labile amino protected backbone having the formula:



2

3 wherein

4 Pg is an acid labile protecting group having the formula:



5

6 wherein


7 each of A₁-A₁₀ is the same or different and is independently selected from the
 8 group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, hydroxy,
 9 methoxy, ethoxy, amino and alkylamino groups; and

10 R⁴ is selected from the group consisting of hydrogen, methyl and ethyl;

- 85 -


11 R⁷ is selected from the group consisting of hydrogen and the side chains of protected or
 12 unprotected naturally occurring α amino acid; and
 13 each of g and h is the same or different and is independently zero or an integer from one
 14 to five.

1 54. The compound of claim 53 wherein the acid labile amino protected backbone has the
 2 formula:



4 wherein

5 Pg is an acid labile protecting group having the formula:



7 wherein

8 each of A₁-A₁₀ is the same or different and is independently selected from the
 9 group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, hydroxy,
 10 methoxy, ethoxy, amino and alkylamino groups; and

11 R⁴ is selected from the group consisting of hydrogen, methyl and ethyl.

1 55. The method of claim 51 wherein the electron donating group is selected from the group
 2 consisting of alkyl, hydroxy and alkoxy groups.


1 56. The method of using the compound of claim 1 as a therapeutic or antisense agent
 2 comprising the step of administering the compound of claim 1 to an organism.

1 57. The method of using the compound of claim 1 as a primer in a polymerase reaction
 2 comprising the step of contacting the compound of claim 1 with a nucleic acid polymer.

1 58. The method of using the compound of claim 1 as a probe for detection of a genetic
 2 material comprising the step of contacting the compound of claim 1 with a nucleic acid polymer.


1/11

Figure 1

 $\text{Mg} = \text{Magnesium}$

2/11

Figure 2



3/11

Figure 3





Figure 4



5/11

Figure 5a




Figure 5b




Figure 6




Figure 7




Figure 8




Figure 9
PNA oligomer sequence H₂N-CTTCTCC-CONH₂






Figure 10
PNA oligomer sequence H₂N-CGCTATAACCC-CONH₂



10/11

Figure 11
PNA/DNA Chimera sequence (crude):
DMBhoc-HN-CACAC-CONH-linker-5'-CCAGT-3'-OH



11/11

Figure 12

PNA/DNA Chimera sequence (purified):
DMBhoc-HN-CACAC-CONH-linker-5'-CCAGT-3'-OH





Figure 13

PNA/DNA Chimera sequence (Gradient Only):
DMBhoc-HN-CACAC-CONH-linker-5'-CCAGT-3'-OH



INTERNATIONAL SEARCH REPORT

Internal Application No	PCT/US 96/07844
-------------------------	-----------------

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07H21/00
--

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
--

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,95 01369 (BUCHARDT OLE ;EGHOLM MICHAEL (DK); NIELSEN PETER E (DK); BERG ROLF) 12 January 1995 see examples 8,9	1-5,7,8, 56-58
X	WO,A,95 14706 (ISIS PHARMACEUTICALS INC) 1 June 1995 see figures 2-5; example 6	1-4,7,8, 56-58
Y	---	36-49
X	WO,A,92 20702 (BUCHARDT OLE ;EGHOLM MICHAEL (DK); NIELSEN PETER EIGIL (DK); BERG) 26 November 1992 see page 17, line 22-24 see page 15, line 37 - page 16, line 4; figures 4,6,25 ---	1-3,7,8, 11-17, 19,20, 22,35, 56-58
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

10 October 1996

05.11.96

Name and mailing address of the ISA

Authorized officer

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Bardili, W

INTERNATIONAL SEARCH REPORT

Internal Application No
PCT/US 96/07844

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,95 08556 (AMERSHAM INT PLC ;REEVE MICHAEL ALAN (GB); BROWN TOM (GB)) 30 March 1995 see page 21; example 6	1-5,7,8, 56-58
Y	---	36-49
P,X	WO,A,95 17403 (PERSEptive BIOSYSTEMS INC) 29 June 1995 see the whole document	11-22,35
Y	EP,A,0 646 596 (BAYER AG) 5 April 1995 see examples 50,53	36-49
Y	HELV. CHIM. ACTA, vol. 51, 1968, pages 614-22, XP002015620 P. SIEBER AND B. ISELIN: "77. Selektive acidolytische Spaltung von Aralkyloxycarbonyl-Aminoschutzgruppen" see the whole document	36-55
Y	J. ORG. CHEM., vol. 54, 1989, pages 1657-64, XP002015621 L.H. KOOLE ET AL.: "Synthesis of Phosphate-Methylated DNA Fragments Using 9-Fluorenylmethoxycarbonyl as Transient Base Protecting Group" see the whole document	36-55
Y	NUCLEOSIDES NUCLEOTIDES, vol. 7, 1988, pages 787-93, XP002015622 A. NYILAS ET AL.: "Arenesulfonylethoxycarbonyl - A Set of Amino Protecting Groups for DNA and RNA Synthesis" see the whole document	36-55
1	-----	

INTERNATIONAL SEARCH REPORT

Information on patent family members			Internal ref.	Application No.
				PCT/US 96/07844
Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO-A-9501369	12-01-95	EP-A- 0717750	26-06-96	
WO-A-9514706	01-06-95	AU-A- 1186095 CA-A- 2177357 EP-A- 0734391	13-06-95 01-06-95 02-10-96	
WO-A-9220702	26-11-92	AU-B- 666480 AU-A- 1880692 AU-A- 1884392 BR-A- 9206049 CA-A- 2109320 CA-A- 2109805 WO-A- 9220703 EP-A- 0586474 EP-A- 0586618 HU-A- 66597 JP-T- 6509063 JP-T- 6506945 NO-A- 934122 NO-A- 934235	15-02-96 30-12-92 30-12-92 27-12-94 25-11-92 26-11-92 26-11-92 16-03-94 16-03-94 28-12-94 13-10-94 04-08-94 11-01-94 20-01-94	
WO-A-9508556	30-03-95	AU-A- 7661794 EP-A- 0720615	10-04-95 10-07-96	
WO-A-9517403	29-06-95	AU-A- 1516495 EP-A- 0736027	10-07-95 09-10-96	
EP-A-0646596	05-04-95	DE-A- 4331011 AU-A- 7161994 CA-A- 2131760 JP-A- 7112969	16-03-95 23-03-95 14-03-95 02-05-95	